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Abstract: Many graphene-based materials (GBNs) applied to therapy and diagnostics (theranostics)
in cancer have been developed. Most of them are hybrid combinations of graphene with other
components (e.g., drugs or other bioactives, polymers, and nanoparticles) aiming toward a synergic
theranostic effect. However, the role of graphene in each of these hybrids is sometimes not clear
enough and the synergic graphene effect is not proven. The objective of this review is to elaborate on
the role of GBNs in the studies evaluated and to compare the nanoformulations in terms of some of
their characteristics, such as therapeutic outcomes and toxicity, which are essential features for their
potential use as bionanosystems. A systematic review was carried out using the following databases:
PubMed, Scopus, and ISI Web of Science (2013–2018). Additional studies were identified manually by
consulting the references list of relevant reviews. Only English papers presenting at least one strategy
for cancer therapy and one strategy for cancer diagnostics, and that clearly show the role of graphene
in theranostics, were included. Data extraction and quality assessment was made by reviewer
pairings. Fifty-five studies met the inclusion criteria, but they were too heterogeneous to combine in
statistical meta-analysis. Critical analysis and discussion of the selected papers are presented.
Keywords: systematic review; graphene-based materials; graphene oxide; reduced graphene oxide;
nano-graphene; graphene quantum dots; theranostics; cancer
1. Introduction
Despite all the efforts invested in therapeutic developments, cancer remains a leading cause
of death worldwide, with a reported mortality of 8.8 million people in 2015. Moreover, the World
Health Organization (WHO) and International Agency for Research on Cancer (IARC) predict a raise
of all cancer cases to 21.2 million by 2030 [1,2]. Current therapeutic regimes for cancer treatment
face important challenges, such as: (i) the use of high doses of actives to ensure their distribution
at the target tissues, (ii) the need to combine several actives to increase therapeutic efficiency and
reduce multidrug resistance mechanisms (MDR), and (iii) damage of healthy tissues and severe toxicity
because of (i) and (ii).
Nanomedicine is potentially one of the best strategies to deal with such challenges, as it provides
breakthrough improvements over classical therapies. Indeed, nanocarrier systems possess extremely
large surface areas convenient for loading multiple therapeutic actives and/or other elements with
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stealth, targeting, triggering, or imaging roles [3,4]. Additionally, the concept of a nanocarrier holds
the promise of taking the actives to the target tissue, thereby reducing the exposure of healthy tissues
to toxic effects. This assumption is further reinforced in cancer, as a preferential accumulation of
nanocarriers in tumor sites has been observed due to the enhanced permeability and retention (EPR)
effect [3,4]. Hence, nanocarriers for cancer therapy can be thoroughly tuned to integrate multiple
strategies in one system (Figure 1):
• Stealth strategies: nanocarriers can be coated with polymers (e.g. Polyethylene glycol, PEG) to
keep them invisible to the immunity system and increase their circulation time;
• Targeting or sensing strategies: nanocarriers can be functionalized with ligands that are recognized
by receptors overexpressed in cancer cell tissues;
• Triggering strategies: nanocarriers’ composition can be sensible to stimulus (e.g. pH, temperature
changes) and releasing their cargo accordingly.
Pharmaceutics 2018, 10, x FOR PEER REVIEW  2 of 48 
 
larg  surface areas convenient for loading multiple therapeutic actives and/or other elements with 
stealth, targeting, triggering, or imaging roles [3,4]. Additionally, the concept of a nanocarrier holds 
the promise of taking the actives to the target tissue, thereby reducing the exposure of healthy tissues 
to toxic effects. This assumption is further reinforced in cancer, as a preferential accumulation of 
nanocarriers in tumor sites has been observed due to the enhanced permeability and retention (EPR) 
effect [3,4]. Hence, nanocarriers for cancer therapy can be thoroughly tuned to integrate multiple 
strategies in one system (Figure 1): 
• Stealth strategies: nanocarriers can be coated with polymers (e.g. Polyethylene glycol, PEG) to 
keep them invisible to the immunity system and increase their circulation time;  
• Targeting or sensing strategies: nanocarriers can be functionalized with ligands that are 
r cognized by r ceptors over xpressed in cancer cell tis ues; 
• Triggering str tegies: nanocarriers’ composition can be sensible to stimulus (e.g. pH, 
temperature changes) and releasing their cargo accordingly. 
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The multipurpose character of the nanocarrier systems has been further explored in the context 
of developing theranostic (therapeutic + diagnostic) tools for fighting cancer that combine several 
therapies with imaging strategies to monitor distribution of the therapeutic agents in the body (Figure 
1). Currently, multiple combinations of different therapeutic and diagnostic strategies are being 
applied to achieve a theranostic effect. As each strategy has inherent advantages and limitations, the 
combination of complementary strategies can result in a synergic theranostic effect. Tables S1, S2, and 
S3 (Supplementary material) summarize some of the most important therapeutic strategies (drug and 
gene therapy, phototherapy (PTT), magnetic hyperthermia (MHT), and photodynamic therapy 
(PDT)), and diagnostic strategies (therapy guiding by fluorescence imaging (FI), two photon 
fluorescence imaging (2PFI), infrared thermal imaging (IR-TI), Raman imaging, X-ray imaging, 
magnetic resonance imaging (MRI), positron emission tomography (PET), single-photon emission 
computed tomography (SPECT), computed tomography (CT), photoacoustic imaging (PAI), and 
ultrasound imaging (USI)) that are being used in nanotheranostic systems [9-24]. 
After its ground breaking and surprising discovery in 2004 [25], graphene—a two-dimensional 
(2-D) nanomaterial made of single-layered carbon atoms packed in a honeycomb lattice—has been 
widely explored for a great number of applications including quantum physics, nanoelectronics, 
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The multipurpose character of the nanocarrier systems has been further explored in the context
of developing theranostic (therapeutic + diagnostic) tools for fighting cancer that combine several
therapies with imaging strategies to monitor distribution of the therapeutic agents in the body
(Figure 1). Currently, multiple combinations of different therapeutic and diagnostic strategies are being
applied to achieve a theranostic effect. As each strategy has inherent advantages and limitations, the
combination of comple entary strategies can result in a synergic theranostic effect. Tables S1, S2 and
S3 (Supplementary material) summarize some of the most important thera eu ic str tegies (drug and
gene therapy, phototherapy (PTT), magn tic hyperthermia (MHT), and photodynamic therapy (PDT)),
and diagnostic strategies (therapy guiding by fluorescence imaging (FI), two photon fluorescence
imaging (2PFI), infrared thermal imaging (IR-TI), Raman imaging, X-ray imaging, magnetic resonance
imaging (MRI), positron emission tomography (PET), single-photon emission computed tomography
(SPECT), computed tomography (CT), photoacoustic imaging (PAI), and ultrasound imaging (USI))
that are being used in nanotheranostic systems [9–24].
After its ground breaking and surprising discovery in 2004 [25], graphene—a two-dimensional
(2-D) nanomaterial made of single-layered carbon atoms packed in a honeycomb lattice—has been
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widely explored for a great number of applications including quantum physics, nanoelectronics, energy
storage, and catalysis [26,27]. Since the first publication on the use of graphene as a nanocarrier system
for anticancer drugs delivery in 2008 [28], graphene and graphene-based nanomaterials (GBNs) have
also captivated the enthusiasm of researchers for its promising biomedical applications, translatable in
an increasing number of publications [29].
GBNs include graphene derivatives, such as graphene oxide (GO), nanographene oxide (NGO),
reduced graphene oxide (rGO), and graphene quantum dots (GQDs), which are also designated
as nano-reduced graphene oxide (nano-rGO) [30,31]. The appealing optical and physicochemical
properties of GBNs are well recognized and have been explored in the development of theranostic
nanosystems for the treatment and diagnostic of cancer [31–33]. In this context, researchers take
advantage of the inherent properties of GBNs (e.g., fluorescence emission, NIR light absorption,
photothermal properties, and typical Raman bands) to develop therapeutic (PTT) and diagnostic (FI,
2PFI, IR-TI, and Raman imaging) approaches [13,16,34]. Alternatively, researchers take advantage of
GBNs’ easy functionalization (owed to the large surface-volume ratio and sp2 network that allows
pi–pi stacking interactions) to add other components that are aimed to enhance or complement GBNs
properties and to achieve synergic theranostic effects [30,32]. These hybrid nanostructures encompass
graphene-based composites (GBCs) that result from GBNs functionalization with nanoparticles,
polymers, imaging probes, radionuclides, drugs, nucleic acids (or other bioactives), photothermal
(PT), and photosensitive (PS) compounds [30,32]. Figure 2 illustrates the different types of GBNs and
provides an example of GBC, as well as some of GBNs most important properties and their main
applications in cancer theranostics.
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composites functionalized with targeting ligands, polymeric coating photosensitizer (For PDT therapy),
drug (for chemotherapy). Near infra-red (NIR) light absorbed by these nanomaterials is required for
PTT, PDT, and to possibly trigger drug releas .
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Despite the multitude of GBNs developed for theranostic purposes, and the increasing amount
of published research articles and reviews on GBNs, it is important to address the question of the
actual function of GO in the systems developed, as well as to evaluate the synergic value of the
GBCs. Indeed, it is not always clear if the functionalized GBNs hybrid systems result in more effective
theranostic strategies than the isolated components, as many studies fail to use appropriate controls to
study the separate elements. Therefore, this lack of clarity drives the need for this systematic review.
Accordingly, the objectives of our study are to systematically review the literature for qualitative
and/or quantitative evidence of synergic effects of GBCs in cancer theranostics, as this is a determinant
to understand the role of GO in the total system developed and to further develop other systems with
improved characteristics. Our secondary aim is to provide an overview of the therapeutic anticancer
efficiency of the nanosystems developed in vitro and/or in vivo. Moreover, the concerns raised with
toxicity and biocompatibility of neat GO are still under extensive debate [35–37]. The toxicity of
GO has been associated with several parameters, among which are included size and topological
defects of GO flakes and their propensity to aggregate [38,39]. Bigger sizes, higher defects, and smaller
colloidal stability may contribute to reactive oxygen species (ROS) generation and consequent cellular
toxicity [38,39]. Furthermore, this type of reactivity is not desirable when, for instance, the objective is
conjugating the GO material with metal-based nanoparticles or metal-based drugs [38]. These concerns
invoked a critical analysis of the reported studies taking into consideration the characterization of GO
in terms of size and colloidal stability and the toxicity evaluation performed in the selected studies.
To the best of our knowledge there are no similar reported reviews emphasizing the role of GBNs in
cancer theranostic and this is the first systematic effort to provide an in-depth critical analysis of the
updated literature to serve as a guide for researchers working in this field.
2. Methods
This review followed PRISMA guidelines [40] and the correspondent checklist is presented in the
supplementary material (Table S4)
2.1. Eligibility Criteria
In this review we analyzed studies proposing the development of GBNs (GO, NGO, rGO, GQDs)
or GBCs for theranostic use in cancer.
Studies were included according to the following criteria: (1) studies were published in English
with full text available; (2) cancer was the target disease; (3) at least one type of GBNs was present in
the proposed nanosystem; (4) studies presented at least one strategy for therapy and one strategy for
diagnostics, and GBNs had a role in at least one of these strategies; and (5) studies were evaluated
in vitro using cellular lines and/or in vivo using animal models. Only research articles were considered,
reviews, commentaries, letters, or editorials were excluded. The references in reviews were, however,
manually consulted.
Of interest are interventions in studies addressing the role of GBNs in the overall therapeutic
effect or diagnostic performance and the synergic effect obtained by GBNs conjugated with other
components. In addition, we considered interventions that evaluate GBNs toxicity as this is also
a relevant factor to obtain an efficient theranostic system. Only studies that evaluate GBNs as a
stand-alone component of the hybrid GBCs and compare the efficiency of the hybrid GBCs with the
isolated components were included.
Primary outcomes were the ones related with theranostic effects: types of strategies used in
therapy and diagnostic and measures of therapeutic efficiency. Secondary outcomes were related with
the characterization of the GBNs developed and with the toxicity of the systems.
2.2. Information Sources, Search Strategy, Study Selection, and Data Collection Process
The literature search strategy was conducted in electronic databases (PubMed, Scopus, and ISI
Web of Science), which was complemented by hand searching in the reference lists of included studies
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or relevant reviews identified through the search. The search was based on a pre-determined series of
keywords related with graphene-based materials and their application in theranostics. The following
keywords were used in PubMed: (((graphene[Title/Abstract]) OR graphene oxide[Title/Abstract]) OR
graphene quantum dots[Title/Abstract]) AND theranostic[Title/Abstract] and these were adapted
to the syntax and subject headings of the other databases. No study design or language limits were
imposed on the search. However, the time of publication was limited to the last 6 years (2013–2018).
The last search was run on 15 October 2018.
To facilitate collaboration among reviewers during the study selection process, literature search
results were uploaded to Endnote X7® software and included in a OneDrive shared folder. Endnote
X7® allowed an automatic exclusion of duplicates from the three databases searched, and a manual
search of duplicates was processed afterwards.
A two-stage process was used during the study selection. In the first stage, the review authors
screened the title, abstract, and keywords against the eligibility criteria. Whenever there was
uncertainty about the eligibility of the publication, the study was not excluded. From this stage
full text of all the eligible and uncertain studies were included to be analyzed in the second stage.
In stage two, review author pairs have screened the full text publications and decided whether these
met the eligibility criteria. Neither of the review authors were blind to journal titles or to authors and
institutions of the studies analyzed. For data collection from the selected studies, we developed a
data extraction sheet, which was pilot tested and optimized accordingly. One review author extracted
the data and the second reviewer author confirmed the extracted data. Any disagreement between
reviewers was resolved after discussing and reaching a consensus.
2.3. Data Items and Quality Assessment
The information extracted from each study included: (1) characteristics of the GBNs developed
in each study, including composition, components ratio, size, surface charge, colloidal stability
analysis, and characterization techniques used; (2) in vitro and/or in vivo models used, detailing
the concentration and doses of the complete system versus the separate components and controls,
as well as the irradiation procedures (potency) power, wavelength, and duration; (3) theranostic
outcome described in terms of diagnostic/therapeutic strategies used and therapeutic efficiency
achieved (measured by hyperthermia effect, cellular viability and tumor volume reduction or evaluated
by histological observations); (4) toxicity outcome (measured by cellular viability, animal weight
variations, and animal survival rate, or evaluated using histological observations).
Following the full-text selection, the studies were assessed for methodological quality via pairs
of reviewers working independently using criteria from QualSyst tool for quantitative/qualitative
studies [41] adapted to meet the specific needs of this systematic review (Table S5 Supplementary
material). All the studies selected met the minimum threshold for inclusion.
3. Results
A total of 55 studies were identified for inclusion in the current review. The search conducted in
the databases retrieved a total of 659 citations (95 from PubMed, 184 from Scopus, and 380 from ISI Web
of Science). A manual selection included 84 references found in updated and extensive reviews that
contained studies on the use of GBNs for cancer theranostics [16,30,42,43]. After duplicate elimination,
490 studies remained.
Of these, 326 studies were rejected after title, abstract, and key words reviewing for not comprising
the eligibility criteria. These rejected articles included: 1 study that was not published in English, 109
reviews, and 6 book chapters. The option to exclude reviews and book chapters was to analyze studies
in their original published form, avoiding introducing bias from analyzing the studies after they have
been analyzed by other authors. Three editorials and three proceedings/short communications were
also excluded because the information contained in these publications was too scarce regarding the
outcomes we wished to analyze. Another eligibility criterion was to include studies that developed
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nanosystems that possessed at least one type of GBN in their composition and the application of
this criterion has rendered the exclusion of 189 studies. Finally, in the first screening phase, we also
excluded studies for which cancer was not the target disease.
The full text of the remaining 164 studies was carefully examined. From this analysis, 109 studies
were rejected for not fitting in the inclusion criteria. The first criterion defined that studies should
possess at least one strategy for therapy and one strategy for diagnostics, otherwise we could not
consider the nanosystem developed as adequate for theranostic applications. Many studies failed to
accomplish this criterion, and the authors often designated their developed nanosystem as a theranostic
system, only because they envisaged the possibility of such a system to be used in both therapy and
diagnostics, but they do not present evidence for both applications. In other cases, authors claimed that
their GBNs were developed for diagnostic purposes, but they had to label them with extrinsic probes
to be able to guide its cellular uptake, which dismisses the purpose of using GBNs or GBCs because of
their intrinsic diagnostic properties. The application of this criterion led to the exclusion of 65 studies.
The second criterion defined that GBNs must have a role in the nanosystem developed contributing
either to diagnostics or therapy. This role can be defined as synergic with other components in the
system such that in the final system the graphene/components individual intrinsic properties are
enhanced. Several authors classified the final effects of their nanosystems as resultant from a synergic
contribution of GBNs and additives, but their study misses evidence of the individual capacities of
GBNs or additives. This second criterion led to the exclusion of 41 studies. Finally, the third criterion
determined the inclusion of studies a bit more advanced than fundamental research and excluded
studies in which the developed nanosystems were neither tested in vitro nor in vivo.
From this screening and eligibility process 55 studies met the abovementioned inclusion criteria,
being eligible to be included in this review (see flow chart diagram in Figure 3).
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Within the complete set of studies, the therapeutic performance was evaluated in cellular [6,49,
50,52,53,55,63,68,70,80–86,89,94], or animal models [46,71,77], or both [5,7,46–48,51,56–62,64,66,69,
72–76,78,79,81,87,88,90–93]. In the case of cellular studies, GBNs were incubated at a defined
concentration or in a range of concentrations and some studies involved the application of GBNs
solely [46,53–55,63,68,71,78,82,91] or conjugated with the exposure to a laser source of a defined
potency, wavelength, and time [5–8,44,45,47–52,56–62,64–67,69,70,72–77,79–81,83–90,92–94]. With the
exception of few studies [45,47,87,94], the laser used is a near infrared light source (NIR) that has
a trigger effect for drug or active release [5,50,51,62,79] or is the promotor of PTT effects [5,6,46,50,
51,58–62,64,66,69,70,72–77,79,86,90,92,93] or PTT+PDT effects [7,48,49,52,56,57,67,81,83,85,88]. Cell
viability was assessed by state-of-the-art methods, such as MTT [5–7,44,45,47–50,53,54,56–60,62,64,
66,68,70,73,74,80,82–86,88,90,92,94], CCK-8 [51,52,63,65,67,69,72,79,87,89,91,93], SRB [75,76,78], trypan
blue [61,82,83], alamar blue [8], or calcein AM [81]. In vivo studies used xenografted animals with
cancer tumor cells, and the GBNs were injected intravenously alone [54,71,78,81,91], or in conjugation
with laser exposition [5,7,8,45–48,51,56–62,64–67,69,72–77,79,87–90,92–94], after which, therapeutic
efficiency was evaluated. Therapeutic effect was measured in terms of: tumor volume, survival rate,
and tumor tissue damage evaluated histologically. In vivo toxicity was assessed via the effects in
body weight or by histological damage of a non-therapeutic form of the nanosystem (e.g., without
laser exposition). In vitro toxicity assessment is often done in the same cancer cell line used for
therapeutic evaluation; however, some studies use a cell line representative of healthy tissues for
this assessment [5,47–49,53,57,58,61,62,67,68,70,81,82,85]. The in vitro toxicity assessment is also called
“dark cell viability” as it is always performed in the absence of laser light exposition to infer the
cytotoxicity of a non-therapeutic form of the nanosystem.
Because physical–chemical factors greatly impact the resultant toxicity and biocompatibility of
graphene, characterization features, such as evaluation of size (lateral dimension and thickness), charge,
surface coating, and colloidal stability, should be also considered as an outcome of the studies [38,39].
However, in this regard, the great majority of the studies failed to provide complete information. From
the 55 studies, only 3 studies have presented these parameters [56,87,91].
The summary of study characteristics for which data were extracted are presented in Table 1 (type
of GBNs, characterization features, and GBNs’ role in therapy or diagnostic, including the reference
of figures from each paper where this role is demonstrated), Table 2 (types of therapeutic strategies,
trigger strategies, and diagnostic strategies), and Table 3 (cellular and animal models, therapeutic
and toxic outcomes in vitro and in vivo, doses of GBNs and actives administrated, actives’ loading
efficiency and laser characteristics).
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Table 1. Summary of characterization features of GBNs, type of graphene nanomaterial, and inclusion criteria based on reported therapeutic and/or diagnostic role of
graphene in the overall system developed. The figures mentioned in this table can be found in each referenced study and represent examples from the revised studies
where therapeutic and/or diagnostic relevance of graphene is clearly illustrated.
Graphene-Based
Nanomaterial Graphene Type Coating
Theranostic
System Size
(D or D× T)
Zeta-Potential/
Colloidal Stability
in Serum
Proven Graphene
Therapeutic Relevance
Proven Graphene
Diagnostic Relevance Ref.
Au@PLA-(PAH/GO)n GO 1.5 µm n.r. USI (Figure 2)s.e. Au@PLA [61]
UCNPs-NGO/ZnPc GO PEG ≈ 300 × 1.5 nm (GO) + 40nm (UCNPs) n.r. PTT (Figure 3 and Figure S4) [85]
GO-HA-Ce6 GO ≈ 440 nm n.r.1 d stability
PTT (Figure 3)
s.e. Ce6 [52]
ICG-GO-FA GO PEG-FA ≈ 200 nm n.r.3 h stability
PTT (Figure S3, Figure 2 and
Figure 3)
s.e. ICG
[86]
GO-AuNS GO ≈ 0.8 µm −19 mV10 days
PTT (Figure 6)
s.e. AuNS [70]
GQD-Cur GO ≈ 150 nm (GQD-Cur)3–6 nm (GQD) n.r. PL (Figure 6) [78]
GO-Abs/Cy7 GO 100–600 × 1.2 nm n.r.
PAT (Figure 3
and Figure 9)
s.e. Cy7
PAI (Figure 3 and Figure 6)
s.e. Cy7 [72]
GDH GO HA ≈ 120 nm (GDH)≈ 30 nm (GO)
n.r.
7 days PTT (Figure 5a) [62]
PheoA+GO:FA-BSA-c-PheoA GO PEG-FA ≈ 180 nm ≈ −30 mVn.r.
PTT + PDT
(Figure 7 and Figure 9)
s.e. Pheo
[47]
GO-PEG-ZnS:Mn-DOX GO PEG-ZnS:Mn n.r. n.r. PL (Figure 4)s.e. ZnS:Mn [53]
CPGA GO PEG ≈ 230 × 15 nm ≈ −25 mV7 d stability
PTT (Figure 3)
s.e. Au and Cy5.5
PAI (Figure 2)
FI (Figure 2)
s.e. Au
[56]
GO@Gd-PEG-FA/DOX GO PEG-FA n.r ≈ −6 mV PTT (Figure 6) [75]
GO/AuNS-PEG/Ce6 GO PEG ≈ 400 × 18 nm ≈ −38 mV1 d stability
PTT (Figure 2b)
s.e. AuNS [87]
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Table 1. Cont.
Graphene-Based
Nanomaterial Graphene Type Coating
Theranostic
System Size
(D or D× T)
Zeta-Potential/
Colloidal Stability
in Serum
Proven Graphene
Therapeutic Relevance
Proven Graphene
Diagnostic Relevance Ref.
GO/Bi2Se3/PVP GO ≈ 150 nm ≈ −18 mV (GO)n.r.
PTT (Figure 5d)
s.e. Bi2Se3
[92]
GO/UCNPs ZnFe2O4 GO PEG ≈ 400 nm ≈ −17 mVn.r.
PTT (Figure 2d)
PDT+PTT (Figure 3)
s.e. UCNPs
[48]
GO/MnWO4/PEG GO PEG ≈ 130 nm ≈ −26 mVn.r. PTT (Figure 3) [5]
LOGr-Pc-LHRH LOGr PEG ≈ 80 nm n.r.n.r.
PTT (Figure 3a
and Figure 6b)
PDT (Figure 6c)
s.e. Pc
[81]
GO-DOX NGO PEG ≈ 30 × 6 nm n.r. PAI (Figure 5) s.e. Cy 5.5 [71]
ICG-FeCl3@GO NGO _ ≈ 40 nm n.r. PTT (Figure 3d)s.e. ICG [83]
GO@Ag-DOX-NGR NGO DSPE-PEG-NGR ≈ 40 nm −29 mV PTT (Figure 6)s.e. Ag [76]
GO-PEG-DVDMS NGO PEG ≈ 20.5 × 1.5 nm n.r.
PTT (Figure 2a, Figure 3a and
Figure 3d)
s.e. DVDMS
[88]
IO/GO-COOH NGO OA ≈ 50 × 20 nm n.r. PTT (Figure 5)s.e. IO
MRI (Figure 3)
s.e. IO [60]
GO-PEG-CysCOOH NGO PEG-CysCOOH < 50 × 2 nm n.r.1 d stability
PTT (Figure 2 and
Figure 4)
s.e. CysCOOH
PAI (Figure 3)
s.e. CysCOOH [73]
Au@NGO NGO ≈ 98 nm ≈ −28 mVn.r.
SERS (Figure 3)
s.e. Au [68]
NGO-PEG-FA NGO PEG-FA ≈ 100 nm n.r PTT (Figure 4, Figure 5,Figure 6 and Figure 7 FI (Figure 3) [7]
NGO-IR-808 NGO PEG ≈ 20–40 × 3 nm n.r.
PTT (Figure 2, Figure 3 and
Figure 7)
s.e. IR-808
FI (Figure 4 and Figure 6)
IR-TI (Figure 7)
s.e. IR-808
[67]
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Table 1. Cont.
Graphene-Based
Nanomaterial Graphene Type Coating
Theranostic
System Size
(D or D× T)
Zeta-Potential/
Colloidal Stability
in Serum
Proven Graphene
Therapeutic Relevance
Proven Graphene
Diagnostic Relevance Ref.
NGO-PEG-ICG/PTX NGO PEG-ICG < 100 × 1 nm ≈ −30 mV14 d stability
PTT (Figure 4, Figure S5 and
Figure 6)
s.e. ICG
FI (Figure 5)
s.e. ICG [91]
NGO-UCNPs-Ce6 NGO OA ≈ 100 nm (GO)+48 nm (UCNPs) n.r.
PTT (Figure S4,
Figure 7 and Figure 8)
PDT+PTT (Figure 3,
Figure 7 and Figure 8)
s.e. UCNPs
[57]
UCNP@NGO NGO OA ≈ 100 nm (GO)+55 nm (UCNPs) n.r.
PTT (Figure 2, Figure 4 and
Figure 5)
s.e. UCNPs
[64]
BSA/nano-rGO rGO BSA ≈ 70 nm ≈ −30 mV30 d stability PTT (Figure 3) PAI (Figure 4 and Figure 5) [74]
rGONM-PEG-Cy7-RGD rGO PEG ≈ 61 nm n.r. PTT (Figure 2) [46]
rGO-Fe2O3@AuNPs rGO NH2-PEG ≈ 610 nm −21.1 mV> 5 h
PTT (Figure 3a)
s.e. Fe2O3@Au NPs
[50]
rGO nanosheets rGO HA ≈ 115 nm ≈ −60 mVn.r.
PTT (Figure 4a
and Figure 5a)
s.e. ICG
[69]
131I-RGO-PEG rGO PEG ≈ 50 × 3.5 nm n.r.7 days
PTT (Figure 2)
s.e. 131I
γ-image (Figure 3)
s.e. 131I [51]
rGO-AuNRVe rGO PEG ≈ 74 nm n.r. PTT (Figure 2)s.e. AuNR
PAI (Figure 5)
s.e. AuNR [79]
anti-EGFR-PEG-rGO@
CPSS-Au-R6G rGO PEG-Anti-EGFR < 200 nm n.r.
PTT (Figure S5
and Figure 7b)
s.e. AuNPs
[6]
ICG-PDA-rGO rGO PDA 1–5 µm × 1 nm n.r.
PTT (Figure 3
and Figure 8)
s.e. ICG
PAI (Figure 4
and Figure 6)
IR-TI (Figure 7)
s.e. ICG
[59]
rGO-GSPs rGO PEG ≈ 100 nm n.r.3 d stability
PTT (Figure 2a
and Figure 2b)
s.e. AuNPs
PAI (Figure 2d
and Figure 2e)
s.e. AuNPs
[66]
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Table 1. Cont.
Graphene-Based
Nanomaterial Graphene Type Coating
Theranostic
System Size
(D or D× T)
Zeta-Potential/
Colloidal Stability
in Serum
Proven Graphene
Therapeutic Relevance
Proven Graphene
Diagnostic Relevance Ref.
rGO-mfHSA rGO mfHSA ≈ 200 nm −25 mV2 d stability PTT (Figure 3c) [93]
FA-PEG-Lip@rGO/Res rGO PEG-FA ≈ 220 nm ≈ −24 mV7 d stability PTT (Figure 7b) IR-TI (Figure 7a) [58]
ArGO rGO APGA ≈ 115 nm ≈ −38 mV28 d stability
PTT (Figure 5b
and Figure 6a) IR-TI (Figure 5a) [77]
AAP10-pDA/rGO rGO pDA 300 nm × 3.5 nm n.r. PTT (Figure 2)s.e. pDA [90]
cGdots GQDs ≈ 5 nm n.r.n.r.
All therapeutic outcomes
came from GQDs
All diagnostic outcomes
came from GQDs [45]
GQDs GQDs 2–6 nm n.r. All therapeutic outcomescame from GQDs
All diagnostic outcomes
came from GQDs [44]
PLA-PEG-grafted GQDs
(f-GQDs) GQDs PLA-PEG ≈ 22 × 1.7 nm
≈ −4 mV
n.r. PL (Figure 4) [55]
AS1411@GQD GQDs ≈ −13 mVn.r.
PTT (Figure 6a
and Figure 6b)
s.e. AS1411
[84]
HA-GQD
-SiO2 NPs
GQDs ≈ 40 nm n.r. PDT (Figure 6)s.e. HA and SiO2 [94]
GQDs@Cys-BHC GQDs ≈ 5 nm n.r. FI (Figure 8) [82]
Fe3O4@SiO2@GQDs-FA/DOX GQDs ≈ 25 nm ≈ −18 mVn.r.
PL (Figure 3)
FI (Figure 5) [80]
GQD-MSN–DOX GQDs 50-80 nm n.r. PTT (Figure 6and Figure 9) [89]
GQD-PEG-P GQDs PEG 8 × 1 nm ≈ + 14 mVn.r. PTT (Figure 3) FI (Figure 5) [49]
DOX@GQD-P-Cy GQDs ≈ 15 nm ≈ −4 mV (w/o) DOXn.r.
FI (Figure 4d–e)
s.e. DOX by FRET [54]
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Graphene-Based
Nanomaterial Graphene Type Coating
Theranostic
System Size
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Colloidal Stability
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DL-GQD-comp GQDs ≈ 220 nm n.r. — PL (Figure 5) [63]
IR780/GQDs-FA GQDs 8.5 × 1.5 nm n.r. PTT (Figure 5a and Figure 5b)s.e. IR780
FI (Figure 6)
IR-TI (Figure 7a)
s.e. IR780
[65]
SCNA
(DOX/GQD) GQDs HTPGS < 5 nm
n.r.
4 h stability PTT (Figure 5e) CLSMI (Figure 4) [8]
Table 1 abbreviations: GO—Graphene oxide; NGO—Nanographene oxide; rGO—Reduced Graphene oxide; GQDs—Graphene Quantum Dots; D—Diameter; D× T—Diameter× Thickness;
d–day(s); n.r.—not reported; s.e.—synergic effect with; CLSMI—confocal laser scanning microscopy imaging; FI—fluorescence imaging; FRET—fluorescence resonance energy transfer;
IR-TI—infrared thermal imaging; MRI—magnetic resonance imaging; PAI—photoacoustic imaging; PAT—photoacoustic therapy; PDT—photodynamic therapy; PL—Photoluminescence;
PTT—photothermal therapy; SERS—Super Enhanced Raman Spectroscopy; USI—ultra sound imaging. AAP10—Antiarrhythmic peptide 10 (promotes bystander effect); Abs—integrin
αvβ3 mAb (targeting ligand); Ag—silver; anti-EGFR—anti-epidermal growth factor receptor (targeting ligand); APGA—amphiphilic poly-γ-glutamic acid; ArGO—rGO coated with
amphiphilic poly-γ-glutamic acid; AS1411—aptamer of 26-base guanine-rich short oligonucleotide (targeting ligand); Au—gold; AuNPs—gold nanoparticles; AuNRVe—gold nanorod
vesicles; AuNR—Gold nanorods; AuNS—Gold nanostars; Bi2Se3—Bismuth Selenide; BHC—Berberine hydrochloride; BSA—bovine serum albumin; Ce6—Chlorin e6 (photosensitizer);
cGdots—carboxylated graphene dots; Cy5.5—Cyanine 5.5 (NIR dye and photosensitizer); Cy7—Cyanine 7 (NIR dye and photosensitizer); Cys—Cysteamine hydrochloride (NIR dye);
Cys-COOH—Cysteine- rich Carboxy-terminal domain CPGA—theranostic probe formed by Cy5.5 (NIR dye) labelled-matrix metalloproteinase-14 (MMP-14) substrate (CP) conjugated
onto the GO/Au complex (GA); CPSS—carbon porous silica nanosheets; Cur—curcumin; DL-GQD-comp—doxorubicin hydrochloride loaded GQD complex; DOX—doxorubicin
hydrochloride; DSPE—1,2-distearoyl-sn-glycero-3-phosphoethanolamine; DVDMS—bis[1-[6,7-bis[2-(sodium carbonate ethyl]-1,3,5,8,-tetramethyl-2-vinyl-porphin-4-yl]ethyl]ether
(photosensitizer); FA—Folic acid (target ligand); FeCl3—Iron chloride; Fe2O3 and Fe3O4—Iron oxide nanoparticles; Gd—Gadolinium; GDH—Graphene–DOX conjugate in HA nanogel;
GSPs—gold superparticles; HA—hyaluronic acid (target ligand); HA-GQD—complex of Hypocrellin A (photosensitizer), HA and GQD; HTPGS—N-acetyl histidine-functionalized
D-α-tocopherol polyethylene glycol 1000 succinate; 131I—Iodine-131 (radioisotope); ICG—NIR fluorescence dye; IO—iron oxide; IR780—IR780 iodide (NIR dye); IR-808—Heptamethine
indocyanine dye (photosensitizer); LHRH—luteinizing hormone-releasing hormone peptide; Lip—Phospholipids; LOGr—low-oxygen graphene; mfHSA—multifunctional human serum
albumin—HSA functionalized with indocyanine green (ICG) and lactobionic acid (LA); MnWO4—manganese tungstate; MSN—mesoporous silica nanoparticles; NGR—Asn-Gly-Arg
peptide (target ligand); OA—Oleic acid; P—porphyrin; PAH—poly (allylamine hydrochloride); Pc—phthalocyanine; P-Cy—Cyanine 5.5 dye conjugated to GQD though a cathepsin
D-responsive peptide (P); PDA or pDA—Polydopamine (reduces GO improves water solubility and biocompatibility and increases NIR absorption); PEG—Polyethylene glycol;
PheoA—Pheophorbide A (photosensitizer); PLA—polylactic acid; PTX—Paclitaxel; PVP—polyvinylpyrrolidone; R6G—Rhodamine 6G; Res—Resveratrol; rGONM—reduced graphene
oxide nanomesh; RGD—arginine–glycine–aspartic acid-based peptide (target ligand); SCNA—size-changeable graphene quantum dot nanoaircraft; SiO2 NPs—silicon dioxide
nanoparticles; UCNPs—upconversion luminescence nanoparticles; ZnFe2O4—Zinc ferrite nanoparticles; ZnPc—Zinc phthalocyanine (photosensitizer); ZnS:Mn—manganese-doped zinc
sulfide nanoparticles.
Pharmaceutics 2018, 10, 282 13 of 45
Table 2. Theranostic strategies of graphene-based nanomaterials containing GO, NGO, rGO and GQDs.
Graphene-Based
Nanomaterial
THERAPY DIAGNOSTIC
Ref.
Drug,
Bioactive, PS,
or Gene
Trigger MHT PTTPAT PDT
Sensing/
Targeting
Therapy Guiding
Optical Non-Optical
FI,
PL
2PFI or
UCLI IR-TI
Raman,
SERS X-ray MRI
PET, CT
SPECT PAI USI
Theranostic strategies of graphene-based nanomaterials containing GO
Au@PLA-(PAH/GO)n + + + [61]
UCNPs-NGO/ZnPc ZnPc(PS) + + + [85]
GO-HA-Ce6 Ce6(PS) HA + + + [52]
ICG-GO-FA + FA + + [86]
GO-AuNS + + [70]
GQD-Cur Cur(Bioactive) + [78]
GO-Abs/Cy7 +PAT Abs + [72]
GDH DOX(Drug)
NIR,
pH
GDH
+ HA + + [62]
PheoA+GO:FA-BSA-c-PheoA PheoA(PS) pH + + FA + [47]
GO-PEG-ZnS:Mn DOX DOX(Drug) pH + [53]
CPGA Cy5.5(PS) + + MMP-14(P) + + + [56]
GO@Gd-PEG-FA/DOX DOX(Drug) + FA + [75]
GO/AuNS-PEG/Ce6 Ce6(PS) + + + [87]
GO/Bi2Se3/PVP + + + + [92]
GO/UCNPs ZnFe2O4
ZnFe2O4
(PS) + + + + + + + [48]
GO/MnWO4/PEG
DOX
(Drug)
NIR,
pH + + + [5]
LOGr-Pc-LHRH Pc(PS) NIR + + + [81]
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Table 2. Cont.
Graphene-Based
Nanomaterial
THERAPY DIAGNOSTIC
Ref.
Drug,
Bioactive, PS,
or Gene
Trigger MHT PTTPAT PDT
Sensing/
Targeting
Therapy Guiding
Optical Non-Optical
FI,
PL
2PFI or
UCLI IR-TI
Raman,
SERS X-ray MRI
PET, CT
SPECT PAI USI
Theranostic strategies of graphene-based nanomaterials containing NGO
GO-DOX DOX(Drug) pH + [71]
ICG-FeCl3@GO
ICG
(PS) + + AGE-Aptamer + [83]
GO@Ag-DOX-NGR DOX(Drug) NIR + NGR + [76]
GO-PEG-DVDMS DVDMS(PS) NIR + + + [88]
IO/GO-COOH + + + [60]
GO-PEG-CysCOOH + + + [73]
Au@NGO DOX(Drug) + [68]
NGO-PEG-FA + + FA + + [7]
NGO-IR-808 IR-808(PS) NIR + + BPEI + + [67]
NGO-PEG-ICG/PTX PTX(Drug) pH + [91]
NGO-UCNPs-Ce6 Ce6(PS) + + + [57]
UCNP@NGO + + + [64]
Theranostic strategies of graphene-based nanomaterials containing rGO
BSA/nano-rGO + + + + [74]
rGONM-PEG-Cy7 RGD + RGD + [46]
rGO-Fe2O3 @AuNPs
DOX
(drug)
NIR
Magnetic + + + [50]
rGO nanosheets + + [69]
131I-rGO-PEG
131I (Radio-
therapy)
NIR + + + [51]
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Table 2. Cont.
Graphene-Based
Nanomaterial
THERAPY DIAGNOSTIC
Ref.
Drug,
Bioactive, PS,
or Gene
Trigger MHT PTTPAT PDT
Sensing/
Targeting
Therapy Guiding
Optical Non-Optical
FI,
PL
2PFI or
UCLI IR-TI
Raman,
SERS X-ray MRI
PET, CT
SPECT PAI USI
rGO-AuNRVe DOX(drug)
NIR
pH + + + [79]
anti-EGFR-PEG-rGO@CPSS-Au-R6G + Anti-EGFR + + [6]
ICG-PDA-rGO + + + [59]
rGO-GSPs + + + [66]
rGO-mfHSA + + [93]
FA-PEG-Lip@rGO/Res Res(Bioactive) + FA + [58]
ArGO + + [77]
AAP10-pDA/rGO AAP10(Peptide) + + [90]
Theranostic strategies of graphene-based nanomaterials containing GQDs
cGdots + + + [45]
GQDs PpIX(PS) + + [44]
PLA-PEG-grafted GQDs
(f-GQDs)
IP ASODN
(Gene) + [55]
AS1411@GQD AS1411(Gene) NIR + AS1411 + [84]
HA-GQD-SiO2 NPs
Hypocrellin
(PS) + + [94]
GQDs@Cys-BHC BHC(Bioactive) pH + [82]
Fe3O4@SiO2
@GQDs-FA/DOX
DOX
(Drug) pH
FA
FRET + + [80]
GQD-MSN-DOX DOX(Drug) + + [89]
GQD-PEG-P P(PS) + + + [49]
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Table 2. Cont.
Graphene-Based
Nanomaterial
THERAPY DIAGNOSTIC
Ref.
Drug,
Bioactive, PS,
or Gene
Trigger MHT PTTPAT PDT
Sensing/
Targeting
Therapy Guiding
Optical Non-Optical
FI,
PL
2PFI or
UCLI IR-TI
Raman,
SERS X-ray MRI
PET, CT
SPECT PAI USI
DOX@GQD–P-Cy DOX(Drug)
Peptide
P FRET + [54]
DL-GQD-comp DOX(Drug) pH HER + [63]
R780/GQDs-FA + FA + + [65]
SCNA (DOX/GQD) DOX(Drug)
NIR +
HTPGS + + + [8]
Table 2 abbreviations: GO—Graphene oxide; NGO—Nano Graphene oxide; rGO—Reduced Graphene oxide; GQDs—Graphene Quantum Dots; PS—photosensitizer; CT—computed
tomography; SPECT—Single Photon Emission Computed Tomography; FI—fluorescence imaging; 2PFI—two photon fluorescence microscopy imaging; FRET—fluorescence resonance
energy transfer; IR-TI—infrared thermal imaging; MHT—magnetic hyperthermia therapy; MRI—magnetic resonance imaging; PAI—photoacoustic imaging; PAT—photoacoustic
therapy; PDT—photodynamic therapy; PET—positron emission tomography; PL—Photoluminescence; PTT—photothermal therapy; SERS—Super Enhanced Raman Spectroscopy;
UCLI—upconversion luminescence imaging; USI—ultrasound image; AAP10—Antiarrhythmic peptide 10 (promotes bystander effect); Abs—integrin αvβ3 mAb (targeting ligand);
Ag—silver; AGE-aptamer—targets melanoma inhibitor of apoptosis protein (ML-IAP) overexpressed in melanoma cells; anti-EGFR—anti-epidermal growth factor receptor (targeting
ligand); APGA—amphiphilic poly-γ-glutamic acid; ArGO—rGO coated with amphiphilic poly-γ-glutamic acid; AS1411—aptamer of 26-base guanine-rich short oligonucleotide (targeting
ligand); ASODN—survivin antisense oligodeoxynucleotide; Au—gold; AuNPs—gold nanoparticles; AuNRVe—gold nanorod vesicles; AuNR—Gold nanorods; AuNS—Gold nanostars;
Bi2Se3—Bismuth Selenide; BHC—Berberine hydrochloride; BPEI—Branched polyethylenimine; BSA—bovine serum albumin; Ce6—Chlorin e6 (photosensitizer); cGdots—carboxylated
graphene dots; Cy5.5—Cyanine 5.5 (NIR dye and photosensitizer); Cy7—Cyanine 7 (NIR dye and photosensitizer); Cys—Cysteamine hydrochloride (NIR dye); Cys-COOH—Cysteine-
rich Carboxy-terminal domain CPGA—theranostic probe formed by Cy5.5 (NIR dye) labelled-matrix metalloproteinase-14 (MMP-14) substrate (CP) conjugated onto the GO/Au
complex (GA); CPSS—carbon porous silica nanosheets; Cur—curcumin; DL-GQD-comp—doxorubicin hydrochloride loaded GQD complex; DOX—doxorubicin hydrochloride;
DSPE—1,2-distearoyl-sn-glycero-3-phosphoethanolamine; DVDMS—bis[1-[6,7-bis[2-(sodium carbonate ethyl]-1,3,5,8,-tetramethyl-2-vinyl-porphin-4-yl]ethyl]ether (photosensitizer);
FA—Folic acid (target ligand); FeCl3—Iron chloride; Fe2O3 and Fe3O4—Iron oxide nanoparticles; Gd—Gadolinium; GDH—Graphene–DOX conjugate in HA nanogel; GSPs—gold
superparticles; HA—hyaluronic acid (target ligand); HA-GQD—complex of Hypocrellin A (photosensitizer), HA and GQD; HER—Herceptin, monoclonal antibody that targets
HER2 Positive Metastatic Breast Cancer (target ligand); HTPGS—N-acetyl histidine-functionalized D-α-tocopherol polyethylene glycol 1000 succinate; 131I—Iodine-131 (radioisotope);
ICG—NIR fluorescence dye; IO—iron oxide; IR780—IR780 iodide (NIR dye); IR-808—Heptamethine indocyanine dye (photosensitizer); LHRH—luteinizing hormone-releasing hormone
peptide; Lip—Phospholipids; LOGr—low-oxygen graphene; mfHSA—multifunctional human serum albumin—HSA functionalized with indocyanine green (ICG) and lactobionic
acid (LA); MMP-14(P)—Peptide substrate of MMP-14, a key endopeptidase that is overexpressed on tumor cell surface; MnWO4—manganese tungstate; MSN—mesoporous silica
nanoparticles; NGR—Asn-Gly-Arg peptide that can selectively recognize CD13 isoform selectively overexpressed in tumor vasculature and certain tumor cells (target ligand); OA—Oleic
acid; P—porphyrin; PAH—poly (allylamine hydrochloride); Pc—phthalocyanine; P-Cy—Cyanine 5.5 dye conjugated to GQD though a cathepsin D-responsive peptide (P); PDA or
pDA—Polydopamine (reduces GO improves water solubility and biocompatibility and increases NIR absorption); PEG—Polyethylene glycol; PheoA—Pheophorbide A (photosensitizer);
PLA—polylactic acid; PpIX—protoporphyrin IX (photosensitizer); PTX—Paclitaxel; PVP—polyvinylpyrrolidone; R6G—Rhodamine 6G; Res—Resveratrol; rGONM—reduced graphene
oxide nanomesh; RGD—arginine–glycine–aspartic acid-based peptide (target ligand); SCNA—size-changeable graphene quantum dot nanoaircraft; SiO2 NPs—silicon dioxide
nanoparticles; UCNPs—upconversion luminescence nanoparticles; ZnFe2O4—Zinc ferrite nanoparticles; ZnPc—Zinc phthalocyanine (photosensitizer); ZnS:Mn—manganese-doped zinc
sulfide nanoparticles.
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Table 3. Therapeutic outcomes and toxicity evaluation of graphene-based nanomaterials containing GO, NGO, rGO and GQDs.
Graphene-Based
Nanomaterial
(GBNs)
In Vitro In Vivo
RefCell
Model
Dark Cell
Viability
[GBNs]
(Method)
NIR Laser
Drug or
Active,
Dose,
AL(wt%)
Therapeutic Outcomes
[GBNs]
(Method)
Animal Model
and Dose
Toxicity
(Method) NIR Laser
Drug or
Active,
Dose,
AL(wt%)
Therapeutic Outcomes
(Method)
Therapeutic outcomes and toxicity evaluation of graphene-based nanomaterials containing GO
Au@PLA-
(PAH/GO)n
HeLa
HUVECs
90% HUVECs
viability with
1000 µg/mL
(Trypan blue)
λ = 808 nm
P = 6.67
W/cm2
t = 6 min
—
• ∆T = 21 ◦C
• 0.1 < IC50 < 0.25
µg/mL
• >80% HeLa cell
death with 0.5
µg/mL
(Trypan blue)
Xenograft mice
(HT1080 cells)
20 mg/Kg
• Minimal effects
(body weight)
λ = 808 nm
P = 2.23 W/cm2
t = 10 min
—
• ∆T = 18.6 ◦C
• Tumor reduced ≈80% in
5d (volume)
[61]
UCNPs-
NGO/ZnPc
KB
HeLa
>90% with
320 µg/mL
(MTT)
- PDT:
λ = 630 nm
P = 50
mW/cm2
t = n.r.
- PTT:
λ = 808 nm
P = 2 W/cm2
t = 10 min
ZnPc
n.r.
• ∆T = 23 ◦C
• 40 < IC50 < 80
µg/mL
• 90% cell death with
320 µg/mL (MTT)
— — — — — [85]
GO-HA-Ce6 A549
≈84% with
1.8 µM Ce6
(CCK-8)
λ = 810 nm
P = 4 W/cm2
t = 8 min
—
• ∆T = 27 ◦C
• IC50 n.r.
• 90% cell death with
1.8 µM Ce6 (CCK-8)
— — — — — [52]
ICG-GO-FA HeLa
≈100% with
20 µg/mL
(MTT)
λ = 808 nm
P = 2 W/cm2
t = 10 min
—
• ∆T ≈ 40 ◦C
• IC50 n.r.
• >90% cell death with
20 µg/mL (MTT)
— — — — — [86]
GO-AuNS SKBR-3MCF-10a
≈95% in
SKBR-3 and
MCF-10a with
40 µg/mL
(MTT)
λ = 808
P = 0.75
W/cm2
t = 2
—
• ∆T = 60 ◦C
• IC50 n.r.
• 81% cell death with
10 µg/mL (MTT)
— — — — — [70]
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Graphene-Based
Nanomaterial
(GBNs)
In Vitro In Vivo
RefCell
Model
Dark Cell
Viability
[GBNs]
(Method)
NIR Laser
Drug or
Active,
Dose,
AL(wt%)
Therapeutic Outcomes
[GBNs]
(Method)
Animal Model
and Dose
Toxicity
(Method) NIR Laser
Drug or
Active,
Dose,
AL(wt%)
Therapeutic Outcomes
(Method)
GQD-Cur HCT166
>90% with
100 µg/mL
(SRB)
— CurAL ≈ 41%
• ∆T = 18 ◦C
• 6 < IC50 < 12.5
µg/mL
• >90% cell death with
100 µg/mL (SRB)
Xenograft mice
(HCT166)
10 mg/Kg
• Minimal effects
(body weight)
• Undetectable
tissue damage
(histological)
— CurAL ≈ 41%
• Tumor growth reduced
4× in 14 d (volume) [78]
GO-Abs/Cy7 U87-MG
≈95% with
42.8 µg/mL
(CCK-8)
λ = n.r.
P =
0.016W/cm2
t = n.r.
—
• 5.3 < IC50 < 10.7
µg/mL
• >90% cell death with
16.05 µg/mL
(CCK-8)
Xenograft mice
(U87-MG cells)
43.4 µg/mouse
• Minimal effects
(body weight)
• Minimal
tissue damage
(histological)
λ = 753 nm
P = 0.02 W/cm2
t = 1 min
—
• Tumor did not grow in
20 d and was 7× smaller
than control
• Survival ≥ 20 d
• Noticeable tumor
tissue damage
(histological)
[72]
GDH MDCKA549
≈80–85%
MDCK cell
viability
with 100
µg/mL
(MTT)
λ = 670 nm
P = 1 W/cm2
t = 5 min
DOX
100 µg/mL
AL n.r.
• ∆T ≈ 30 ◦C
• IC50 = 50 µg/mL
• 70–75% A549 cell
death with 100
µg/mL (MTT)
Xenograft mice
(A549 cells)
2.5 mg/Kg
• Minimal effects
(body weight)
• Minimal
tissue damage
(histological)
λ = 670 nm
P = 1 W/cm2
t = 30 min
DOX
n.r.
• ∆T ≈ 17 ◦C
• Tumor reduced ≈40% in
18 d (volume)
• Noticeable tumor
tissue damage
• (histological)
[62]
PheoA+GO:
FA-BSA-c-PheoA
B16F10
MCF-7
100% with
0.375 µg/mL
(MTT)
λ = 670 nm
P = 0.13
W/cm2
t = 10 min
—
• ∆T = 6 ◦C
• IC50 < 0.375 µg/mL
• 95% cell death with
1.5 µg/mL (MTT)
Xenograft mice
(B16F10 cells)
2 mg/Kg
• Minimal effects
(body weight)
λ = 670 nm
P = 0.13 W/cm2
t = 10 min
—
• Tumor growth reduced
3× in 14 d (volume) [47]
GO-PEG-ZnS:
Mn-DOX
HeLa;
CHO-K1
100% with
1000 µg/mL
(w/o DOX)
(MTT)
—
DOX
300 µg/mL
AL ≈ 10%
• IC50 < 2.5 µg/mL
• 85% cell death with
10 µg/mL (MTT)
— — — — — [53]
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Dark Cell
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and Dose
Toxicity
(Method) NIR Laser
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AL(wt%)
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(Method)
CPGA SCC7
≈70% with
200 µg/mL
(MTT)
λ = 808 nm
P = 0.3 W/cm2
t = 10 min
—
• ∆T = 23 ◦C
• 50 < IC50 <100
µg/mL
• 80% cell death with
200 µg/mL (MTT)
Xenograft mice
(SCC7 cells)
10 mg/Kg
• Minimal effects
(body weight)
λ = 808 nm
P = 0.75 W/cm2
t = 10 min
—
• ∆T = 15.9 ◦C
• Tumor abl. in 6 d
(volume)
[56]
GO@Gd-PEG-
FA/DOX MCF-7
≈85% with
10 µg/mL
(w/o DOX)
(SRB)
λ = 808 nm
P = 2.5 W/cm2
t = 5 min
DOX
10 µg/mL
AL≈94%
• ∆T = 22.1 ◦C
• IC50 n.r.
• 80% cell death with
10 µg/mL (SRB)
Xenograft mice
(S180 cells)
10 mg/Kg
• Minimal effects
(body weight)
λ = 808 nm
P = 2 W/cm2
t = 5 min
DOX
5 mg/kg
AL ≈ 94%
• ∆T = 9.6 ◦C
• Tumor growth reduced
7× in 12 d (volume)
• Noticeable tumor
tissue damage
(histological)
[75]
GO/AuNS-
-PEG/Ce6 EMT6
>95% with
100 µg/mL
(CCK-8)
λ = 660 nm
P = 2 W/cm2
t = 8 min
—
• ∆T = 50 ◦C
• IC50 < 0.375 µg/mL
• ≈80% cell death
with 150 µg/mL
(CCK-8)
Xenograft mice
(EMT6 cells)
10 mg/kg
• Minimal effects
(body weight)
• Minimal
tissue damage
(histological)
λ = 660 nm
P = 3 W/cm2
t = 10 min
—
• ∆T = 20 ◦C
• Tumor abl. in 14 d
(volume)
• Noticeable tumor
tissue damage
(histological)
[87]
GO/Bi2Se3/
PVP HeLa
>90% with
75 µg/mL
(MTT)
λ = 808 nm
P = 0.3 W/cm2
t = 10 min
—
• ∆T = 33 ◦C
• 25 < IC50 < 50
µg/mL
• ≈90% cell death
with 100 µg/mL
(MTT)
Xenograft mice
(HeLa)
0.2 mg/mouse
• Minimal effects
(body weight)
• Minimal tissue
damage with
0.4 mg/mouse
(histological)
λ = 808 nm
P = 0.4 W/cm2
t = 5 min
—
• ∆T = 23 ◦C
• Tumor abl. in 2 d
(volume)
• Noticeable tumor
tissue damage
(histological)
[92]
GO/UCNPs
ZnFe2O4
HeLa;
L929
80% with
500 µg/mL
(MTT)
λ = 980 nm
P = 0.8 W/cm2
t = 15 min
—
• ∆T ≈ 55 ◦C
• IC50 < 15.6 µg/mL
• ≈90% cell death
with 500 µg/mL
(MTT)
Xenograft mice
(U14 cells)
n.r.
• Minimal effects
(body weight)
• Minimal
tissue damage
(histological)
λ = 980 nm
P = 0.8 W/cm2
t = 15 min
—
• ∆T ≈ 35 ◦C
• Tumor did not grow in
14 d and was 7× smaller
than control (volume)
• Noticeable tumor
tissue damage
(histological)
[48]
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AL(wt%)
Therapeutic Outcomes
(Method)
GO/MnWO4/PEG
4T1
HUVEC
90% and 80%
(4T1 and
HUVEC cell)
with 100
µg/mL
(MTT)
λ = 808 nm
P = 0.6 W/cm2
t = 10 min
DOX
5 µg/mL
AL ≈ 55%
• ∆T ≈ 55 ◦C
• IC50 < 50 µg/mL
• ≈90% cell death
with 100 µg/mL
(MTT)
Xenograft mice
(U14 cells)
0.6 mg/mouse
• Minimal effects
(body weight)
• Minimal
tissue damage
(histological)
λ = 808 nm
P = 0.6 W/cm2
t = 10 min
DOX
0.2
mg/mouse
AL ≈ 55%
• ∆T ≈ 27 ◦C
• Tumor abl. in 12 d.
(volume)
• Noticeable tumor
tissue damage
(histological)
[5]
LOGr-Pc-LHRH A2780/ADRBC
• 90%
(A2780/AD)
with 125
µg/mL
(MTT)
• Minimal
hemolytic
activity
(RBC)
with 44
µg/mL
λ = 690 nm
P =
0.95W/cm2
t = 15 min
Pc
4 µg/mL
• ∆T ≈ 35 ◦C
• IC50 < 1.8 µg/mL
• ≈95% cell death
with 7 µg/mL
(Calcein AM)
Xenograft mice
(A2780/AD
cells)
1 mg/Kg
— — —
• Only diagnostic by
fluorescence
tumor imaging
[81]
Therapeutic outcomes and toxicity evaluation of graphene-based nanomaterials containing NGO
GO-DOX — — — — —
Xenograft mice
(H1975 cells)
n.r.
• Undetectable
tissue damage
(histological)
• Minimal effects
(body weight)
—
DOX
8 mg/kg
AL = 133%
• Tumor reduced ≈75% in
14 d (volume) [71]
ICG-FeCl3@GO G361 —
λ = 785 nm
P = 1 W/cm2
t = 20 min
ICG
n.r.
• IC50 n.r.
• 99% cell death
[GBNs] n.r (MTT,
Trypan blue)
— — — — — [83]
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AL(wt%)
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GO@Ag-DOX-
NGR MCF-7
≈90% with
10 µg/mL
(SRB)
λ = 808 nm
P = 2 W/cm2
t = 3 min
DOX
4 µg/mL
AL ≈ 82%
• ∆T = 18 ◦C
• 0.5 < IC50 < 1 µg/mL
• ≈94% cell death
with 4.88 µg/mL
(SRB)
Xenograft mice
(S180)
6.1 mg/Kg
• Minimal effects
(body weight)
• Minimal
tissue damage
(histological)
λ = 808 nm
P = 2 W/cm2
t = 3 min
DOX
5 mg/kg
AL ≈ 82%
• Tumor did not grow in
13 d and was 5× smaller
than control
• Survival≥ 14 d
• Noticeable tumor
tissue damage
(histological)
[76]
GO-PEG-DVDMS PC9
≈70% with
3 µg/mL
(MTT)
- PDT:
λ = 630 nm
P = 3 J/well
t = n.r.
- PTT:
λ = 808 nm
P = 1 W/cm2
t = 3 min
DVDMS
n.r
• IC50 ≈ 0.25 µg/mL
• 90% cell death with 3
µg/mL (MTT)
Xenograft mice
(PC9 cells)
1 mg/Kg
• Minimal effects
(body weight)
- PDT:
λ = 630 nm
50 J
t = n.r.
- PTT:
λ = 808 nm
P = 1 W/cm2
t = 10 min
DVDMS
2 mg/kg
• ∆T = 25 ◦C
• Tumor abl. in 2 d
(volume)
[88]
IO/GO-COOH HeLa
95% with
[Fe] = 200
µg/mL
(MTT)
λ = 808 nm
P = 2 W/cm2
t = 5 min
—
• ∆T = 60 ◦C
• IC50 n.r.
• ≈100% cell death
with 150 µg/mL
(MTT)
Xenograft mice
(S180 cells)
37.5 µg /mouse
• Minimal effects
(body weight)
λ = 808 nm
P = 1 W/cm2
t = 5 min
—
• ∆T > 37 ◦C
• Tumor abl. in 2 d
(volume)
• Survival ≥ 60 d
[60]
GO-PEG-
CysCOOH 4T1
≈100% with
250 µg/mL
(MTT)
λ = 808 nm
P = 0.5 W/cm2
t = 3 min
—
• ∆T ≈ 25 ◦C
• IC50 n.r.
• >90% cell death with
250 µg/mL (MTT)
Xenograft mice
(4T1)
450 µg/mouse
• No
detectable effects
(body weight)
• Minimal
tissue damage
(histological)
λ = 808 nm
P = 0.5 W/cm2
t = 5 min
—
• ∆T ≈ 38 ◦C
• Tumor abl. in 2
d(volume)
• Survival ≥ 60 d
[73]
Au@NGO HeLa cells
≈80% with
200 µg/mL
(MTT)
—
DOX
25 µg/mL
AL ≈ 2%
• 0.375 < IC50 = 1.25
µg/mL
• >90% cell death with
2 µg/mL (MTT)
— — — — — [68]
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AL(wt%)
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NGO-PEG-FA B16F0
≈90% with
75 µg/mL
(MTT)
• PTT
λ = 808 nm
P = 0.32 W/cm2
t = 15 min
• PTT+PDT
λ = 980 nm
P = 0.32 W/cm2
t = 18 min
—
- PTT
• ∆T ≈ 18 ◦C
• 50 < IC50 < 75
µg/mL
• 65% cell death
with 75 µg/mL
- PTT+PDT:
• ∆T ≈ 11 ◦C
• IC50 = 25
µg/mL
• 85% cell death
with 75 µg/mL
(MTT)
Xenograft mice
(B16F10 cells)
8 mg/Kg
—
• PTT
λ = 808 n
P = 0.25 W/cm
t = 8 mi
• PTT+PDT
λ = 980 nm
P = 0.25 W/cm2
t = 10 min
—
- PTT:
• ∆T = 8.8 ◦C
• Tumor slow
growth in 14 d
• Survival ≤ 32 d
- PDT+PTT:
• ∆T = 1.8 ◦C
• Tumor abl. in 14 d
(volume) Survival
≥ 40 d
[7]
NGO-IR-808 A549;Lewis lung
Negligible
toxicity with
10 µM
(CCK-8)
λ = 808 nm
P = 2 W/cm2
t = 5 min
—
• ∆T = 34 ◦C
- A549 cells:
• IC50 = 5
µg/mL
• 95% cell death
with 10 µM
- Lewis lung cells:
• 2.5 < IC50 <5
µg/mL
• 100% cell death
with 10 µM
(CCK-8)
Xenograft mice
(A549; Lewis
lung cells)
10 mg/Kg
• No
detectable effects
(body weight)
• Minimal
tissue damage
(histological)
λ = 808 nm
P = 1 W/cm2
t = 5 min
—
• ∆T = 23.5 ◦C
• Tumor abl. in 3–4 d.
(volume)
• Noticeable tumor
tissue damage
(histological)
[67]
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Graphene-Based
Nanomaterial
(GBNs)
In Vitro In Vivo
RefCell
Model
Dark Cell
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[GBNs]
(Method)
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Drug or
Active,
Dose,
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Drug or
Active,
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AL(wt%)
Therapeutic Outcomes
(Method)
NGO-PEG-
ICG/PTX MG-63
≈100% with
200 µg/mL
(w/o PTX)
(CCK-8)
—
PTX
100 µg/mL
AL ≈ 90%
• IC50 = 20 µg/mL
• 90% cell death with
100 µg/mL of PTX
(CCK-8)
Xenograft mice
(MG-63)
10 mg/kg
• No
detectable effects
(body weight)
• Minimal
tissue damage
(histological)
—
PTX
9 mg/kg
AL ≈ 90%
• Tumor abl. in 15 d
(volume)
• Noticeable tumor
tissue damage
(histological)
[91]
NGO-UCNPs-Ce6 HeLa;L929
>95% with
800 µg/mL
(MTT)
λ = 808 nm
P = 0.72
W/cm2
t = 10 min
—
• ∆T = 47 ◦C
• IC50 = 25 µg/mL
• 85% cell death with
800 µg/mL (MTT)
Xenograft mice
(U14 cells)
n.r.
• No
detectable effects
(body weight)
• Minimal
tissue damage
(histological)
λ = 808 nm
P = 0.72 W/cm2
t = 10 min
—
• Tumor did not grow in
14 d and was 9× smaller
than control (volume)
• Noticeable tumor
tissue damage
(histological)
[57]
UCNP@
NGO 4T1
>90% with
400 µg/mL
(MTT)
λ = 808 nm
P = 2 W/cm2
t = 10 min
—
• ∆T = 47 ◦C
• IC50 = 100 µg/mL
• >90% cell death with
400 µg/mL
(MTT, Cytometry)
Xenograft mice
(4T1 cells)
n.r.
• Minimal effects
(body weight)
• Minimal
tissue damage
(histological)
λ = 808 nm
P = 1 W/cm2
t = 5 min
—
• ∆T = 23 ◦C
• Tumor abl. in 6 d
(volume)
[64]
Therapeutic outcomes and toxicity evaluation of graphene-based nanomaterials containing rGO
BSA/nano-rGO MCF-7cells
100% with
0.04 µg/mL
(MTT)
λ = 808 nm
P = 6 W/cm2
t = 5 min
—
• ∆T = 30 ◦C
• IC50 = 0.108 µg/mL
• 80% cell death with
0.15 µg/mL (MTT)
Xenograft mice
(MCF-7)
20 mg/kg
• Undetectable
tissue damage
(histological)
λ = 808 nm
P = 0.6 W/cm2
t = 5 min
—
• ∆T = 18 ◦C
• Noticeable tumor
tissue damage
(histological)
[74]
rGONM-PEG-
Cy7-RGD — — — — —
Xenograft mice
(U87MG cells)
0.2 mg/mouse
• Minimal effects
(body weight)
λ = 808 nm
P = 0.1 W/cm2
t = 7 min
—
• Tumor abl. in 3 d
(volume)
• Survival ≥ 90 d
[46]
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Nanomaterial
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Model
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AL(wt%)
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(Method)
rGO-
Fe2O3@Au
NPs
HeLa
≈90% with
50 µg/mL
(MTT)
λ = 808 nm
P = 2 W/cm2
t = 5 min
DOX
n.r.
AL≈100%
• ∆T = 30 ◦C
• 10 < IC50 < 20
µg/mL
• 97% cell death with
50 µg/mL (MTT)
— — — — — [50]
rGO nanosheets KB
≈95% with
20 µg/mL
(CCK-8)
λ = 808 nm
P = 1.2 W/cm2
t = 3 min
—
• ∆T = 51 ◦C
• IC50 n.r.
• >90% cell death with
20 µg/mL (CCK-8)
Xenograft and
orthotopic mice
(KB cells)
5 mg/kg
• Minimal effects
(body weight)
λ = 808 nm
P = 1.2 W/cm2
t = 3 min
—
• ∆T = 13 ◦C Tumor abl.
in 3 d (volume)
• highest % of
apoptotic cells
(histological)
• Survival ≥ 50 d
[69]
131I-RGO-PEG 4T1
≈90% with
200 µg/mL
(CCK-8)
λ = 808 nm
P = 0.5 W/cm2
t = 10 min
131I
100 µCi
• ∆T = 51 ◦C
• IC50 n.r.
• 90% cell death with
100 µg/mL (CCK-8)
Xenograft and
orthotopic mice
(4T1cells)
10 mg/kg
• Minimal effects
(body weight)
λ = 808 nm
P = 0.2 W/cm2
T = 20 min
131I
200 µCi/
mouse
• ∆T ≈ 18 ◦C
• Tumor abl. in 16 d
(volume)
• Noticeable tumor
tissue damage
(histological)
[51]
rGO-AuNRVe U87MG
100%
with 2.4 nM
(CCK-8)
λ = 808 nm
P = 0.25
W/cm2
t = 5 min
DOX
6.4 µg/mL
AL ≈ 65%
• IC50 = 0.63 µg/mL
(DOX)
• 90% cell death with
6.4 µg/mL of DOX
(CCK-8)
Xenograft and
orthotopic mice
(U87MG)
10 mg/kg
• Minimal effects
(body weight)
• Minimal
tissue damage
(histological)
λ = 808 nm
P = 0.25 W/cm2
t = 5 min
DOX
AL ≈ 65%
• ∆T = 13 ◦C
• Tumor abl. in 14 d
(volume)
• Survival≥ 40 d
[79]
anti-EGFR-PEG-rGO@
CPSS-Au-R6G A549
100% with
100 µg/mL
(MTT)
λ = 808 nm
P = 0.5 W/cm2
t = 5 min
—
• IC50 n.r.
• 72% cell death with
100 µg/mL (MTT)
— — — — — [6]
ICG-PDA-rGO 4T1
≈90% with
20 µg/mL
(MTT)
λ = 808 nm
P = 0.6 W/cm2
t = 5 min
—
• ∆T = 30 ◦C
• IC50 = 10 µg/mL
• 85% cell death with
40 µg/mL (MTT)
Xenograft and
orthotopic mice
(4T1 cells)
200 µg/mouse
• Minimal effects
(body weight)
λ = 808 nm
P = 0.6 W/cm2
t = 5 min
—
• Tumor abl. in 3 d
(volume)
• Survival ≥ 40 d
[59]
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rGO-GSPs U87MG
≈100% with
100 µg/mL
(MTT)
λ = 808 nm
P = 0.8 W/cm2
t = 5 min
—
• ∆T = 40 ◦C
• IC50 n.r.
• 85% cell death with
100 µg/mL (MTT)
Xenograft mice
(U87MG cells)
200 µg/mouse
• No detectable
tissue damage
(histological)
λ = 808 nm
P = 0.8 W/cm2
t = 5 min
—
• ∆T = 28 ◦C
• Tumor abl. in 2 d
(volume)
• Noticeable tumor
tissue damage
(histological)
• Survival ≥ 40 d
[66]
rGO-mfHSA HepG2
≈100% with
20 µg/mL
(CCK-8)
λ = 808 nm
P = 2 W/cm2
t = 5 min
—
• ∆T ≈ 30◦C
• IC50 = 10 µg/mL
• >90% cell death
(CCK-8)
Xenograft mice
(HepG2)
200 µg/mouse
• No
detectable effects
(body weight)
λ = 808 nm
P = 1 W/cm2
t = 10 min
—
• ∆T ≈ 20 ◦C
• Tumor growth. reduced
4× in 20 d (volume)
[93]
FA-PEG-Lip@rGO/
Res
A549
MCF-7
>90% with
80 µg/mL
(w/o Res)
(MTT)
λ = 780 nm
P = 0.6 W/cm2
t = 10 min
Res
56 µg/mL
AL ≈ 70%
• IC50 ≈ 10 µg/mL
• >98% cell death with
80 µg/mL (MTT)
Xenograft mice
(MCF-7 cells)
2.2 mg/kg
• No
detectable effects
(body weight)
λ = 780 nm
P = 0.6 W/cm2
t = 5 min
Res
AL ≈ 70%
• ∆T = 17 ◦C
• Tumor abl. in 10 d
(volume)
[58]
ArGO — — — — —
Xenograft mice
(SCC7 cells)
5 mg/kg
• 100% survival
one day after
i.v.;
• normal blood
test results (50
mg/kg)
λ = 808 nm
P = 1.5 W/cm2
t = 3 min
—
• ∆T = 16 ◦C
• Tumor abl. in 10 d
(volume)
• Survival≥ 50 d
[77]
AAP10-pDA/rGO MCF-7
≈100% with
160 µg/mL
(MTT)
λ = 808 nm
P = 1.5 W/cm2
t = 5 min
AAP10
50 nM
AL ≈
0.024%
• ∆T = 18 ◦C
• IC50 n.r.
• ≈80% cell death
with 120 µg/mL
(MTT)
Xenograft mice
(4T1 cells)
0.3 mg/mouse
• Minimal effects
(body weight)
• No detectable
tissue damage
(histological)
λ = 808 nm
P = 1.5 W/cm2
t = 5 min
AAP10
AL ≈
0.024%
• ∆T = 25 ◦C
• Tumor abl. in 7 d
(volume)
• Noticeable tumor
tissue damage
(histological)
[90]
Therapeutic outcomes and toxicity evaluation of graphene-based nanomaterials containing GQDs
cGdots MDA-MB231
>70% with
500 µg/mL
(MTT)
λ = 670 nm
P = 0.3 W/cm2
t = 30 min
—
• ∆T ≈ 25 ◦C
• IC50 ≤ 50 µg/mL
• >70% cell death with
500 µg/mL (MTT)
Xenograft mice
(MDA-MB231
cells)
75 µg/mouse
• No
detectable effects
(body weight)
λ = 670 nm
P = 0.3 W/cm2
t = 30 min
irr. every
other day
—
• ∆T = 17 ◦C
• Tumor growth reduced
2× in 14 d (volume)
• Noticeable tumor
tissue damage (histological)
[45]
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GQDs HeLa
>90% with
1.8 µM
(MTT)
λ = 670 nm
P = 6.5
mW/cm2
t = 10 min
PpIX
n.r.
• 0.036 < IC50 < 0.09
µM
• >80% cell death with
1.8 µM (MTT)
Xenograft mice
(MDA-MB231
cells)
80 µg/mouse
• No
detectable effects
(body weight)
λ = 400–800 nm
P = 80 mW/cm2
t = 10 min
irr. day 1 and 7
PpIX
n.r.
• Tumor abl. in 20 d
(volume) [44]
PLA-PEG-grafted
GQDs
(f-GQDs)
HeLa
≈90% cell
viability with
140 µg/mL
(MTT)
—
IP and
ASODN
50 nM
• IC50 n.r.
• 32% cell death with
14 µg/mL
(Cytometry)
— — — — — [55]
AS1411@
GQD A549
100% cell
viability with 5
µM
(MTT)
λ = 808 nm
P = 2 W/cm2
t = 10 min
AS1411n.r.
• ∆T ≈ 13 ◦C (in H2O)
• 50% cell death with 5
µM (MTT)
— — — — — [84]
HA-GQD
-SiO2 NPs
HeLa
100% with 4
µM
Hypo-crellin
(MTT)
λ = 470 nm Hypocre-llin4 µM
• IC50 n.r.
• 80% cell death with 4
µM Hypocrellin
(MTT)
— — — — — [94]
GQDs@Cys-BHC
L929
HeLa
MDA-MB-231
Low toxicity
with
200 µg/mL
(w/o BHC)
(Trypan blue,
MTT)
—
BHC
≈0.4 mM
AL ≈ 88%
• IC50 = 200 µg/mL
• 40–50% cell death
with 200 µg/mL
(Trypan blue, MTT)
— — — — — [82]
Fe3O4@SiO2
@GQDs-FA/DOX HeLa
>90% with
50 µg/mL
(MTT)
λ = 808 nm
P = 0.3 W/cm2
t = 10 min
—
• IC50 = 1 µg/mL
• 85% cell death with
50 µg/mL (MTT)
— — — — — [80]
GQD-MSN-
-DOX 4T1
≈95% with
100 µg/mL
(CCK-8)
λ = 808 nm
P = 2.5 W/cm2
t = 3 min
DOX
4.5 µg/mL
AL ≈ 4.8%
• ∆T ≈ 20 ◦C
• IC50 n.r.
• ≈90% cell death
with 100 µg/mL
(CCK-8)
— — — — — [89]
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[GBNs]
(Method)
NIR Laser
Drug or
Active,
Dose,
AL(wt%)
Therapeutic Outcomes
[GBNs]
(Method)
Animal Model
and Dose
Toxicity
(Method) NIR Laser
Drug or
Active,
Dose,
AL(wt%)
Therapeutic Outcomes
(Method)
GQD-PEG-P A549MCF-7
100% with
100 µg/mL
(MTT)
λ = 980 + 636
nm
P = 0.72
W/cm2
t = 10 min
—
• ∆T = 30 ◦C
• IC50 n.r.
• 90% cell death with
100 µg/mL (MTT)
— — — — — [49]
DOX@GQD-
-P-Cy 4T1
≈95% with
4 µg/mL
(w/o DOX)
(MTT)
—
DOX
3.3 µg/mL
AL ≈
82.5%
• IC50 = 1 µg/mL
• ≈98% cell death
with 4 µg/mL (MTT)
Xenograft mice
(4T1 cells)
1 µg /mouse
• Minimal effects
(body weight) —
DOX
0.8 µg
/mouse
AL ≈
82.5%
• Tumor growth
decreased 4× (volume)
• Noticeable tumor
tissue damage
(histological)
• Survival ≤ 20 d
[54]
DL-GQD-comp BT-474
≈90% with
100 µg/mL
(w/o DOX)
(CCK-8)
—
DOX
8.8 µM
AL ≈ 5.3%
• 50 < IC50 < 100
µg/mL
• ≈80% cell death
with 100 µg/mL
(CCK-8)
— — — — — [63]
IR780/GQD-FA HeLa
≈90% with
30 µg/mL
(CCK-8)
λ = 808 nm
P = 1 W/cm2
t = 5 min
—
• ∆T = 28 ◦C
• IC50 = 10 µg/mL
• ≈98% cell death
with 30 µg/mL
(CCK-8)
Xenograft mice
(HeLa cells)
2 mg/kg
• No
detectable effects
(body weight)
λ = 808 nm
P = 1 W/cm2
t = 5 min
—
• ∆T = 23 ◦C
• Tumor abl. in 6 d
(volume)
• Survival ≥ 60 d
[65]
SCNA
(DOX/GQD) RG2
≈100% with
10 µg/mL
(w/o DOX)
(alamar blue)
λ = 808 nm
P = 2 W/cm2
t = 5 min
DOX
2 µg/mL
AL n.r.
• IC50 n.r.
• ≈75% cell death
with 10 µg/mL
(alamar blue)
Xenograft mice
(RG2 cells)
0.2 mg/mouse
• No
detectable effects
(body weight)
λ = 808 nm
P = 2 W/cm2
t = 10 min
DOX
2 µg/mL
AL n.r
• ∆T = 10 ◦C
• Noticeable tumor
tissue damage
(histological)
[8]
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Table 3 abbreviations: GBNs—Graphene-based nanomaterials; GO—Graphene oxide; NGO—Nanographene oxide; rGO—Reduced Graphene oxide; GQDs—Graphene Quantum
Dots; AL (wt%)—Active’s loading; d–day(s); n.r.—not reported; abl.—completely ablated; w/o—without; NIR laser– Near infrared laser; (λ, P, and t)—characteristics of the
laser: wavelength; power and time; ∆T—temperature increase; IC50—concentration of GBNs required to kill 50% of cells; PTT—photothermal therapy; PDT—photodynamic
therapy; AAP10—Antiarrhythmic peptide 10 (promotes bystander effect); Abs—integrin αvβ3 mAb (targeting ligand); Ag—silver; AGE-aptamer—targets melanoma inhibitor
of apoptosis protein (ML-IAP) overexpressed in melanoma cells; anti-EGFR—anti-epidermal growth factor receptor (targeting ligand); APGA—amphiphilic poly-γ-glutamic
acid; ArGO—rGO coated with amphiphilic poly-γ-glutamic acid; AS1411—aptamer of 26-base guanine-rich short oligonucleotide (targeting ligand); ASODN—survivin antisense
oligodeoxynucleotide; Au—gold; AuNPs—gold nanoparticles; AuNRVe—gold nanorod vesicles; AuNR—Gold nanorods; AuNS—Gold nanostars; Bi2Se3—Bismuth Selenide;
BHC—Berberine hydrochloride; BPEI—Branched polyethylenimine; BSA—bovine serum albumin; Ce6—Chlorin e6 (photosensitizer); cGdots—carboxylated graphene dots;
Cy5.5—Cyanine 5.5 (NIR dye and photosensitizer); Cy7—Cyanine 7 (NIR dye and photosensitizer); Cys—Cysteamine hydrochloride (NIR dye); Cys-COOH—Cysteine- rich
Carboxy-terminal domain CPGA—theranostic probe formed by Cy5.5 (NIR dye) labelled-matrix metalloproteinase-14 (MMP-14) substrate (CP) conjugated onto the GO/Au
complex (GA); CPSS—carbon porous silica nanosheets; Cur—curcumin; DL-GQD-comp—doxorubicin hydrochloride loaded GQD complex; DOX—doxorubicin hydrochloride;
DSPE—1,2-distearoyl-sn-glycero-3-phosphoethanolamine; DVDMS—bis[1-[6,7-bis[2-(sodium carbonate ethyl]-1,3,5,8,-tetramethyl-2-vinyl-porphin-4-yl]ethyl]ether (photosensitizer);
FA—Folic acid (target ligand); FeCl3—Iron chloride; Fe2O3 and Fe3O4—Iron oxide nanoparticles; Gd—Gadolinium; GDH—Graphene–DOX conjugate in HA nanogel; GSPs—gold
superparticles; HA—hyaluronic acid (target ligand); HA-GQD—complex of Hypocrellin A (photosensitizer), HA and GQD; HER—Herceptin, monoclonal antibody that targets HER2
Positive Metastatic Breast Cancer (target ligand); HTPGS—N-acetyl histidine-functionalized D-α-tocopherol polyethylene glycol 1000 succinate; 131I—Iodine-131 (radioisotope);
ICG—NIR fluorescence dye; IO—iron oxide; IR780—IR780 iodide (NIR dye); IR-808—Heptamethine indocyanine dye (photosensitizer); LHRH—luteinizing hormone-releasing
hormone peptide; Lip—Phospholipids; LOGr—low-oxygen graphene; mfHSA—multifunctional human serum albumin—HSA functionalized with indocyanine green (ICG)
and lactobionic acid (LA); MMP-14(P)—Peptide substrate of MMP-14, a key endopeptidase that is overexpressed on tumor cell surface; MnWO4—manganese tungstate;
MSN—mesoporous silica nanoparticles; NGR—Asn-Gly-Arg peptide that can selectively recognize CD13 isoform selectively overexpressed in tumor vasculature and certain tumor
cells (target ligand); OA—Oleic acid; P—porphyrin; PAH—poly (allylamine hydrochloride); Pc—phthalocyanine; P-Cy—Cyanine 5.5 dye conjugated to GQD though a cathepsin
D-responsive peptide (P); PDA or pDA—Polydopamine (reduces GO improves water solubility and biocompatibility and increases NIR absorption); PEG—Polyethylene glycol;
PheoA—Pheophorbide A (photosensitizer); PLA—polylactic acid; PpIX—protoporphyrin IX (photosensitizer); PTX—Paclitaxel; PVP—polyvinylpyrrolidone; R6G—Rhodamine 6G;
Res—Resveratrol; rGONM—reduced graphene oxide nanomesh; RGD—arginine–glycine–aspartic acid-based peptide (target ligand); SCNA—size-changeable graphene quantum
dot nanoaircraft; SiO2 NPs—silicon dioxide nanoparticles; UCNPs—upconversion luminescence nanoparticles; ZnFe2O4—Zinc ferrite nanoparticles; ZnPc—Zinc phthalocyanine
(photosensitizer); ZnS:Mn—manganese-doped zinc sulfide nanoparticles. Methods: Alamar Blue—cell proliferation assay designed to measure cell proliferation and cytotoxicity in
various cell lines; Calcein AM—non-fluorescent, hydrophobic compound that easily permeates intact live cells; it can be used in a cell viability assay once, by hydrolysis, converts
in calcein, a hydrophilic and strongly fluorescent compound; CCK-8—Cell Counting Kit-8 that allows sensitive colorimetric assays for the determination of cell viability in cell
proliferation and cytotoxicity assays; MTT—colorimetric assay for assessing cell metabolic activity based on conversion of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide to formazan; SRB –Sulforhodamine B assay used for cell density determination, based on the measurement of cellular protein content; Trypan Blue—dye exclusion test, used
to determine the number of viable cells present in a cell suspension. Cells: 4T1—mouse breast carcinoma cell line; A2780/AD—multidrug resistant human ovarian carcinoma cell line;
A549—lung cancer cell line; B16F0—mouse melanoma cell line; B16F10—murine melanoma cell line; BT474—human breast cancer cell line; CHO-K1—Chinese Hamster Ovary cell
line; EMT6—mouse breast cancer cell line; G361—human malignant melanoma cancer cells; H1975—lung adenocarcinoma cells; HeLa- human cervical cancer cells; HCT166—human
colon cancer cells; HepG2—human hepatocellular carcinoma cell line; HT1080—human fibro-sarcoma cells; HUVEC - Human umbilical vein endothelial cells; KB—Human KB
epidermal carcinoma cells; L929—mouse fibroblasts; Lewis lung—mouse lung carcinoma cells; MCF-7—human breast adenocarcinoma cell line; MCF-10—normal breast cells;
MDA-MB-231—breast cancer cells; MDCK—Canine Cocker Spaniel Kidney non-cancerous cell line; MG-63—human osteosarcoma cell line; RBC—red blood cells; PC9—human
adenocarcinoma cell line; RG2—mouse glioblastoma cell line; S180—murine sarcoma cancer cell line; SCC7—mouse squamous cell carcinoma cell line; SKBR-3—human epithelial
breast cancer cells; U87MG—human glioblastoma astrocytoma cells; U14—mouse uterine cervical carcinoma cells; U87MG—human glioblastoma astrocytoma cells.
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From the observation of Table 1 it is possible to conclude that most studies used GO (17 studies),
followed by the other types of GBNs: rGO (13 studies), GQDs (13 studies), and NGO (12 studies). This
preference must relate to the enriched oxygen surface of GO (carboxylic, epoxy and hydroxyl groups)
that favor a broad extent of interactions and functionalization opportunities [30,31].
From the observation of Table 2 it is possible to conclude that the most explored therapy modality
was PTT (44 studies), followed by PDT (16 studies), and chemotherapy (16 studies). The most
explored synergic effect was the combination of PTT+PDT (14 studies), followed by chemotherapy+PTT
(8 studies). Doxorubicin (DOX) was the anticancer drug used in most chemotherapy modalities
(16 studies) and the drug release was often adjuvated by a trigger effect (10 studies), such as NIR
and pH changes. The most explored diagnostic modality was FI (27 studies), followed by IRTI (20
studies) and PAI (13 studies). All studies presented the combination of at least one therapy strategy
in combination with at least one diagnostic strategy, and the most complex system [48] combined
two therapeutic strategies (PTT+PDT) with four diagnostic strategies (2PFI+MRI+CT+PAI). Figure 4
presents a Venn chart with the relative proportion of therapy and diagnostic strategies explored in the
55 studies analyzed.
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4. Discussion
Because the study designs, interventions, and reported outcomes varied noticeably, we focused on
the description of the studies for which we systematically organized their results in Tables 1–3. We will
discuss their relevance, and their limitations, in a qualitative critical analysis instead of a meta-analysis.
The aim of this systematic review was to critically analyze the theranostic role of GBNs when it is
the only component of the nanosystem or is instead incorporated in more complex nanosystems. First,
the notion of theranostics presupposes the existence of a combined therapeutic and diagnostic strategy
in the same system. However, not so uncommonly, studies present their developed nanosystems
as a theranostic tool, even when they lack experimental evidence for both strategies. Though these
studies may develop promising systems for theranostic applications, they should not be considered as
such, only based in a theoretical assumption. Many of these studies have been introduced in previous
reviews as theranostic nanosystems, but we have excluded them from the current review, as the
inclusion criterion defined that only experimentally proved theranostic systems should be considered
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The reason for the systematic scrutiny also came from the perception that the GBNs’ component
of the system is not always analyzed for its individual effects either in therapy or in diagnostic, and
without this analysis, its role in the entire system is compromised. It also compromised the assumption
of a synergic effect of the entire system when the individual effects of each individual component are
not evaluated.
Considering these aims, we will propose a discussion based on the role of GBNs in therapy,
diagnostics, and toxicity of the overall theranostic systems, and we will also comment on the
perspectives of a future clinical translation.
4.1. Role of Graphene-Based Nanomaterials in Therapy
4.1.1. Overview of the Different Therapeutic Strategies
GBNs intrinsic properties have converted these nanomaterials into a very attractive choice as
drug and gene delivery systems. The combination of a 2-D structure with a large surface area and
the existence of delocalized pi electrons, as well as chemical polar groups that exist mainly on the GO
surface, grants high drug loading ratios of lipophilic and hydrophilic actives [32]. Indeed, within the
chemical surface moieties of GO, the epoxy and hydroxyl groups can establish hydrogen bonds with
actives, while the carboxylic acid group offers negative surface charge for electrostatic interactions
with positively charged molecules (Figure 2). Furthermore, actives can establish hydrophobic and
pi-pi stacking interactions with GBNs [32]. Finally, active loading can be achieved via covalent and
noncovalent surface functionalization of GBNs. Such a diverse range of possible interactions has given
GBNs an important role in drug delivery, as it has been documented that drug loading ratios can
achieve 200 wt%, which is exceptionally high compared to any other drug nanocarrier system [95].
Among the studies included in this review, DOX is the most used drug [5,8,50,53,54,62,63,68,74–
76,79,89], as it can be efficiently loaded in GBNs via a simple pi-pi stacking interaction, or alternatively,
it can be bonded to GBNs via ester linkages [62,76]. The drug loading achieved with the GBN
systems can in fact be higher than that achieved with other nanocarrier systems. For instance, the
commercial liposomal formulations of DOX, Caelyx®, and Doxil® have a drug loading of 16 wt%,
while most GBNs formulations of this review (Table 3) are able to reach higher drug loading values,
from 55 wt% to 133 wt% [5,50,54,71,75,76,79]. However, the drug loading capacity is not the only
appealing feature of loading DOX in GBNs. The possibility of exploring triggering strategies that can
release the drug under different stimuli is also attractive, as the idea is to carry the drug throughout
the body with minimal release in the healthy tissues, and a higher release in the cancer target tissues.
In the cases that DOX has been bonded to GBNs via ester linkage, this linkage can be broken by
physiological esterases that are often overexpressed in cancer tissues or the drug release can be triggered
externally using NIR radiation [62,76]. NIR radiation is a triggering strategy commonly used to release
DOX from GBNs [5,8,62,76,79]. Moreover, DOX is positively charged at physiological pH, while the
carboxylic groups of GBNs are negatively charged, which favors an electrostatic interaction. This
was used as a triggering strategy for a pH-dependent release of DOX in several studies in the current
review [5,53,63,71,79,80]. As in the tumor microenvironment, intracellular lysosomes and endosomes
are acidic, the carboxylic groups of graphene become non-ionized and the electrostatic interaction
between drug and GBNs ceases. Additionally, one study has used an alternative triggering strategy by
functionalizing GBNs with a pH labile linker that, in the face of the acidic tumor environment, releases
the drug [8]. Conjugation of GBNs with iron oxide nanoparticles confers superparamagnetic properties
to the overall nanosystem, and this was another strategy explored for a pH-assisted magnetic triggering
of DOX [50].
Besides the use of GBNs as carriers of DOX, one study has used GBNs loaded with paclitaxel
(PTX), also with a very successful drug loading (90 wt%) [91] in comparison with the commercial
PTX formulations Taxol® (1 wt%) and Abraxane® (11 wt%). In this study, PTX was non-covalently
immobilized on the NGO surface via a pi-pi stacking interaction and hydrogen bonding, and PTX
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release was also triggered using pH. At acidic pH (5.0), characteristic of tumor tissues and intracellular
lysosomes, PTX was released in 30% greater quantities than at blood and healthy tissues pH (7.4) [91].
However, the authors of this study do not present an explanation for such pH-triggered drug release,
and this is not as evident as in the case of DOX, since PTX is neutral at all the pH values tested and
NGO surface groups will be more protonated at acidic pH, favoring the hydrogen bonding with PTX.
Other than drugs, bioactives have also been used with a chemotherapy purpose. Natural
compounds with anticancer effects have hampered pharmaceutical uses due to their small
bioavailability and poor stability [96]. Nanocarriers have given these compounds new prospects
for clinical application by improving bioavailability and protecting them from early metabolization
or degradation [96]. GBNs offer the additional advantage of providing higher payloads than the
conventional nanocarriers, and in this review, GBNs were used to load curcumin (Cur) [78], resveratrol
(Res) [58], and berberine hydrochloride (BHC) [82] with loadings of ≈ 41 wt%, 70 wt%, and 88 wt%,
respectively. In contrast to Cur and Res that were loaded in GBNs by pi-pi stacking interactions,
BHC was functionalized on the surface of GQDs by means of a biocompatible linker (Cys-HCl). At
acidic pH characteristic of tumor cell tissues, there was an increased release of the bioactive resulting
from breaking of the bonds between BHC and GBNs, therefore pH was also used in this case as a
triggering mechanism.
In an interesting approach to chemotherapy, Yu and coworkers have used the peptide
H2N-Gly-Ala- Gly-4Hyp-Pro-Tyr-CONH2 (AAP10), which is a bioactive that has its mode of action
based on a bystander effect [90]. The bystander effect refers to the ability of injured cells in transmitting
cytotoxic signals to the nearby cells, which become more sensitive to chemotherapy and PTT damages.
This effect is primarily controlled by a connexin-mediated gap-junction intercellular communication
(GJIC). Sadly, most cancer cells possess deficient GJIC, and in addition, tumors are 3-D structures,
which can restrain the efficacy of the bystander effect. Consequently, the inexistence of a bystander
effect impairs the propagation of damage between cells and some cells become shaded to therapy.
Thus, both chemotherapy and PTT fail to kill all tumor cells, which results in cancer recurrence.
Therefore, enhancing the bystander effect in tumor cells is an encouraging strategy to increase PTT
and chemotherapy efficacy. In this regard, AAP10 was loaded in rGO to elevate the protein activity of
connexins, thereby promoting the transfer of toxic signals or toxics between adjacent cells in tumors
via a bystander effect [90].
The large surface of GBNs is also attractive for the development of a multipotential nanosystems
that comprise, not only the drug, but also other components to enhance therapeutic performance
and reduce toxicity. This is the case of targeting or sensing ligands that are used to specifically
bind to overexpressed receptors existent in cancer cells, reducing internalization by normal cells,
thereby reducing off-target toxicity. The overall targeting strategies used in the studies reviewed are
summarized in Table 4:
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Table 4. List of targeting moieties used to functionalize GBNs and direct them to cancer cells.
Ligands Function Ref.
Abs Targets integrin (αvβ3) receptor overexpressed in cancer cells [72]
AGE-aptamer Targets melanoma inhibitor of apoptosis protein (ML-IAP) overexpressed inmelanoma cells [83]
Anti-EGFR Targets the epidermal growth factor receptor (EGFR) of lung cancer cells [6]
AS1411 Aptamer specific to malignant melanoma [84]
BPEI Targets the organic anion transporting polypeptides (OATPs) overexpressed incancer cells [46]
FA Targets folic acid receptors overexpressed in cancer cells [7,47,58,65,75,80,86]
HA Targets CD44 receptors, a cell surface adhesion receptor that is highly expressedin many cancers and regulates metastasis [62]
HER Targets HER2+ receptors in breast cancer cells [63]
HSA-LA Generates galactose residues that targets asialoglycoprotein receptor (ASGP-R),highly expressed on the surface of hepatocellular carcinoma cells (HCC) [93]
MMP-14(P) Targets the overexpressed endoperoxidase in tumor cell membrane [56]
NGR Targets CD13 isoform selectively overexpressed in tumor vasculature and certaintumor cells [76]
RGD Targets integrin αvβ3 mAb overexpressed in cancer cells [46]
Table abbreviations: Abs—integrin αvβ3 mAb; anti-EGFR—anti-epidermal growth factor receptor;
AS1411—aptamer, 26-base guanine-rich short oligonucleotide; BPEI—Branched polyethylenimine, cationic polymer
that can be used to condense nucleic acids in gene therapy or as targeting agent; FA—Folic acid; HA—hyaluronic
acid; HER—Herceptin, monoclonal antibody; HSA-LA—human serum albumin functionalized with lactobionic acid
(LA); MMP-14(P)—metalloproteinase-14 substrate; NGR—Asn-Gly-Arg peptide; RGD—arginine–glycine–aspartic
acid-based peptide.
The same favorable properties of GBNs referred to above for drug and bioactive delivery
applications can be extended to gene delivery applications. Indeed, even in the absence of cationic
groups, GBNs have demonstrated the capacity to effectively condense genetic material through pi-pi
stacking interactions, protecting the nucleic acids from endonucleases degradation. Many studies have
emphasized the role of GBNs in gene delivery in vitro [30]; however, there is a need to establish
their potential in vivo, paying special attention to its safety profile, transfection efficiency, and
biodistribution. The only two studies included in this systematic review that are aimed at genetic
therapy, although promising in vitro, also lack in vivo validation [84,94].
Besides chemotherapy, and contrastingly to a previous review that covered studies reported from
2012–2014 [97], we found that the most explored therapeutic strategy of GBNs is PTT [5,6,46,50,51,58–
62,64,66,69,70,72–77,79,86,90,92,93]. In the time frame of that review, chemotherapy was the focus of
using GBNs, while in the last 6 years, covered by this systematic review, researchers have shown the
appealing role of GBNs in PTT.
By being 2-D materials, GBNs have a broad absorption in the NIR region (700–1100 nm) due
to their narrow band gap that expands the light absorption to NIR region. Upon NIR radiation
absorption, GBNs can convert it into thermal energy, which causes a temperature rise and cellular
damage or death via hyperthermia (please see Table S1 of supplementary materials for a more detailed
explanation of the PTT mechanism). Simultaneously, this process of temperature rise reduces GO
and releases gases, creating a microcavitation environment from gas bubbles formation and collapse.
The microcavitation environment, if created in a cellular media, is in turn responsible for cell death [98].
Most GBNs have been reported to have a good photothermal conversion efficiency that enables
reaching a high PTT efficiency with a low power density of NIR light, and this potentiality was used
in two studies herein reviewed, where PTT efficiency was exclusively obtained from GQDs NIR
absorption capacity [44,45]. In other studies, the PTT efficiency of GBNs was further enhanced via
conjugation with other narrow bandgap materials due to their increased NIR absorption, such as:
Au based nanomaterials [6,61,66,68,70,79,87], Ag based nanomaterials [76]; cyanine and cysteamine
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based dyes (e.g., Cy5.5, Cy7, CysCOOH) [56,72,73,85]; IR780 iodide dye [65]; indocyanine green
dye [59,69,86,93]; and Bi2Se3 nanoparticles. Another strategy to increase cell death by hyperthermia is
to combine magnetic hyperthermia with PTT efficiency via the conjugation of GBNs with magnetic
nanoparticles made of transition metals, such as: Fe, Ni, Co, Mn and its oxides (e.g., MnWO4, and
IO-supermagnetic iron oxide nanoparticles) [5,60]. In comparison with GO, rGO has 6 times higher
NIR absorption, and as such, rGO are more efficient GBNs for PTT applications (Figure 2). Therefore,
another strategy used in these studies was coating GBNs with polydopamine (pDA), as it reduces GO
to rGO, thereby increasing NIR absorption [59,90].
Although the studies selected in this systematic review demonstrate the important role of GBNs
in the PTT therapeutic strategy, some limitations can be also pointed out. First, the photothermal
conversion efficiency should be calculated and reported, since a high demonstrable photothermal
conversion efficiency avoids the use of high power NIR laser density that can cause serious burn
wounds and tissue shrinking [99]. In fact, some authors mentioned that upon NIR laser irradiation,
a noticeable black round mark persisted on mice skin, which is direct evidence of the generation of
excessive local heating [61]. Accordingly, there is a big discrepancy of power used from study to study,
varying from small values of 6.5 mW/cm2 [44] to high values of 6.67 W/cm2 [61], and without the
value of photothermal conversion efficiency, it is very difficult to analyze which GBNs or GBCs are
more effective. Second, photostability of the overall GBCs should also be demonstrated.
Besides PTT, PAT is another therapeutic strategy in which photon energy is converted in an
acoustic shockwave (PA wave) to kill cancer cells, being different from PTT where photon energy is
converted to heat to damage or kill cancer cells [72]. Therefore, in PTT, there is an application of a
continuous laser radiation, whereas in PAT the duration of the laser pulse is shorter than the thermal
diffusion time [72]. This strategy was used by Qin and co-workers to conjugate a dye with GO, and
the fluorescence quenching of this dye promoted by GO reduced the release of the absorbed energy
via a radiative transition while increasing the non-radiative transition [72].
Recently, GBNs have also been used in PDT for its capacity of forming complexes with
photosensitizers (PS) via pi-pi stacking and hydrophobic interactions. The different PS used in
the studies reviewed can be identified in Table 2. The energy transfer from the laser NIR light
source to PS will cause reactive oxygen species generation (ROS), which are ultimately responsible
for cell damage and death (please see Table S1 of supplementary materials for a more detailed
explanation of the PDT mechanism). This strategy was used in several studies of this review that
generally took advantage of the synergistic effect of the combination of two therapy modalities: PTT +
PDT [7,45,47–49,52,56,57,67,81,83,85,87,88]. These strategies can be a good alternative to drug delivery
as they do not require the cellular internalization of GBNs. Given the wide ranges of lateral size
dimensions and thickness of the materials reported herein (Table 1), it would be difficult for them all
to succeed in a context of drug/gene delivery, where a control of sizes <100 nm is required to enter the
cell and <40 nm to access the nucleus. However, the restricted depth reached by UV light debilitates
the PDT effect. Accordingly, some studies have used the strategy of combining GBNs with UCNPs,
which can convert the high depth penetration NIR light into high-energy photons (UV/vis) [48,57,85].
4.1.2. Critical Comparison of Therapeutic Outcomes
By analyzing Table 3, it is possible to conclude that all the studies reported were successful in
killing cancer cells in vitro; however, when evaluating therapeutic outcomes in vivo, it is possible
to find bigger differences in the sense that some formulations show much higher anti-tumor effects
by ablating the tumor completely [5,7,44,46,51,56,58,59,64–67,69,73,77,79,87,88,90–92], while other
formulations are not able to achieve a complete ablation of the tumor [45,47,48,54,57,60–62,71,72,75,76,
78,93].
One immediate analysis is that GBNs made of rGO were more successful in achieving a tumor
elimination (9 studies out of 10 were able to ablate tumor between 3 to 16 days), most probably because
in all studies, PTT was the therapeutic strategy alone or in combination with other strategies and rGO
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presents a high NIR absorbance (6 times higher than GO or NGO), thereby possessing intrinsic higher
photothermal conversion to kill cells via hyperthermia. Besides the PTT efficiency, the high tumor
uptake might be the explanation for the success of these formulations in tumor ablation. Table S6 of the
supplementary materials summarizes the biodistribution information of some of these formulations
than can be correlated to the successful therapeutic outcomes obtained. In three other studies with rGO
nanomaterials that were able to eradicate the tumor, there is no biodistribution information available
to understand tumor uptake and accumulation [59,66,90]. However, some characteristics of these
formulations might explain their success in tumor ablation. rGO-GSPs formulation was able to ablate
tumors in 2 days with a survival rate ≥40 days using PTT as therapy strategy [66]. The reason for such
a successful therapeutic outcome might be related to the synergic effect obtained by conjugating rGO
(already a high thermal conversion nanomaterial) with gold superparticles (GSPs), which endowed
the rGO-GSPs formulation with NIR absorption and enhanced photothermal conversion properties
due to the strong plasmonic coupling effect [66]. Indeed, after administration of this formulation, the
surface temperature of the tumor increased rapidly from ≈30 ◦C to ≈58 ◦C within 5 min of 808 nm
laser irradiation at a power density of 0.8 W/cm2 [66]. AAP10-pDA/rGO formulation was also very
effective at promoting tumor ablation in 7 days [90]. In this case the success of the formulation might
be related with the bystander effect of the AAP10 peptide that, as already explained, allows for damage
effects resulting from PTT to be effectively transferred from one cell to the adjacent cells [90]. Finally,
two formulations containing both rGO and ICG were developed for a PTT strategy, but the therapeutic
outcome obtained was quite different. ICG-PDA-rGO formulation was able to ablate tumors in 3
days with a survival rate ≥40 days [59], while rGO-mfHSA was only able to reduce tumor growth by
4-fold in 20 days [93]. Although biodistribution data is not available for comparison purposes, and
although both formulations contain two synergic components for PTT (ICG + rGO), the most effective
formulation contains pDA that has been described as able to increase NIR absorption, thereby being a
third additional synergic component for PTT [59].
In GBNs formulations made of GO or NGO loaded with DOX for a chemotherapy strategy
used as only strategy [71] or combined with PTT [62,75,76], the therapeutic outcomes are improved
regarding the use of free DOX, but the tumors are not totally ablated. The only exception is observed
for the formulation GO/MNWO4/PEG that was able to eliminate tumor in 12 days (and no remission
observed until the end of the study after 16 days) [5]. In this formulation there is a synergic effect
between chemotherapy (DOX) and PTT (GO+MnWO4) as the components alone were less effective
than the combined system: (i) DOX alone was not able to ablate tumor, but the growth rate of tumor
volume decreased about 1.5-fold in comparison to the control; (ii) PTT strategy alone (GO+MnWO4)
had a lower effect than the entire synergic formulation, since it ablated the tumor in 12 days, but it
then started to grow until the 16th day. Other GO or NGO based formulations have also used DOX
chemotherapy combined with PTT [62,75,76]; however, it was less efficient than GO/MnWO4/PEG.
A possible explanation for this fact is that in the later formulation, laser treatment was applied twice
(6 and 24h post-injection), and the biodistribution assays that quantified Mn indicated that after 24 h
post-administration, there was still significant intratumor concentration of the nanocarriers (7% ID/g),
thus the second laser irradiation might have potentiated the PTT effect (Table S7 of the supplementary
materials)).
The GO-DOX formulation was the only case of GO-based formulations where DOX was used
in a single chemotherapy strategy, and GO was merely a nanocarrier for DOX [71]. GO-DOX
formulation was also not able to ablate tumors, but after 14 days of administration, reduced the
tumor by approximately 75% [71]. The treatment efficacy also improved 6.5-fold in comparison to
free DOX, suggesting a high tumor uptake efficiency of this formulation whose dimensions indicate
cell internalization (30 × 6 nm) [71]. Despite not presenting a synergic therapy and not being able to
eliminate the tumor, GO-DOX presents the highest loading efficiency of DOX (133.32 wt%) in GBNs,
which may account to the good therapeutic outcome reached. Furthermore, authors of this study have
evaluated the effect of GO-DOX formulation in angiogenesis, as this is considered a parameter to
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predict metastasis and to evaluate chemotherapy effect. They concluded that the GO-DOX suppressed
3 times as much tumor angiogenesis when compared with DOX [71].
The chemotherapy effect of PTX loaded in NGO based formulation (NGO-PEG-ICG/PTX) was
able to promote tumor ablation in 15 days [91]. In this case, PTX was also used as a single chemotherapy
strategy, and GO was merely a nanocarrier. Despite not presenting a synergic therapy, this formulation
had a small lateral size that assures good tumor cellular uptake, and this was confirmed through
biodistribution studies that indicated a significant intratumor concentration of the nanonarriers (29.1%
ID/g) 24 h after treatment (Table S7 of the supplementary materials).
Since PTT is not so efficient in GO-based nanosystems as it is in rGO based nanosystems, the
success of therapeutic depends largely on combined PTT+PDT or multiple PTT strategies. Except for
three studies [47,48,57], all the formulations based in NGO or GO and using a combined PTT+PDT
strategy effectively ablated tumors in a short period of time (2 to 14 days) [7,56,67,87,88]. Besides
the PTT+PDT synergic combination, the effective cellular uptake of the formulations might be the
explanation for their success in tumor ablation. Table S7 of the supplementary materials summarizes
the biodistribution information available for some of these formulations than can be correlated to the
successful therapeutic outcomes obtained. Two studies that were effective in tumor eradication do
not present biodistribution data, so we could not correlate tumor accumulation with the therapeutic
outcome [7,88]. However, their efficiency in tumor ablation can be correlated with: (i) the use of
synergic PTT+PDT strategy, (ii) their small lateral dimensions that might favor tumor cell uptake,
and (iii) the use of two laser irradiation conditions that for sure potentiate the cellular damage via
hyperthermia and ROS. Indeed, the formulation GO-PEG-DVDMS possesses a combination of PTT
strategy (conferred by NGO) and PDT strategy (conferred by DVDMS) and therapy was achieved
upon double irradiation of tumors with a laser of λ = 630 nm (for PDT treatment) and with a laser of λ
= 808 nm (for PTT treatment) [88]. Whereas, the formulation NGO-PEG-FA possesses a combination
of PTT+PDT strategy (both conferred by NGO) with a laser of λ = 630 nm (for PDT treatment) and
with a laser of λ = 808 nm (for PTT treatment) and a laser of λ = 980 nm (for PDT+PTT treatment) [7].
Among the three studies that were not able to ablate tumors, two of them had better performance as
the tumors did not grow during the entire time course of the experience (14 days) and at the end of the
study the tumor volume in treated animals was 7× [48] or 8× [57] smaller than the tumor volume in
the untreated animals (control). Both studies lack biodistribution evaluation and thus it is difficult
to analyze the reasons why these formulations were not able to ablate tumors, but we can at least
hypothesize that their similar effect of stabilizing tumor growth can be related to the fact of both
possessing UCNPs, which, as previously referred, may increase PDT tissue penetration. The other case
of a combined PTT and PDT strategy with GO (PheoA+GO:FA-BSA-c-PheoA) was the least successful
of all, not being able to avoid tumor growth, although the rate of tumor growth in treated animals was
3× smaller after 14 days than the tumor growth of untreated animals (control) [47]. Authors of this
study present biodistribution evaluation and showed that after injection, PheoA+GO:FA-BSA-c-PheoA
preferentially accumulated at the tumor (around 2-fold at 3 h), but also accumulated in skin (less than
Pheo alone) and the liver [47]. At 24 h post-injection, PheoA+GO:FA-BSA-c-PheoA is only located
in the tumor while Pheo is still in the skin. Despite the successful tumor accumulation, there was
not a successful tumor ablation as occurred in other studies, and we can hypothesize that this can be
related not with the absence of tumor uptake, but with the laser irradiation used. The authors of this
study [47] used a single laser for PDT and PTT purposes and this laser is out of the NIR range (λ =
670 nm instead of >800 nm), which is not so adequate to achieve a PTT-effective treatment. It is also
worthwhile to mention that another formulation (GO/AuNS-PEG/Ce6) that was able to ablate tumors
also used a single irradiation out of the NIR range (λ = 660 nm instead of >800 nm), but in this case,
the PTT effect was not only dependent of GO but it was reinforced by the conjugation with AuNS that
increases thermal conversion efficiency [87]. Notwithstanding this, the capacity to ablate the tumor
using GO/AuNS-PEG/Ce6 took a longer time than the other studies (14 days compared with 2 to
6 days) [56,67]. Moreover, in the treatment with GO/AuNS-PEG/Ce6, the potency of the laser was
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significantly higher (3 W/cm2 for 10 min) and the doses administrated were also significantly higher
(10 mg/kg) [87] compared with the treatment with PheoA+GO:FA-BSA-c-PheoA that used a low laser
potency of the laser (0.13 W/cm2 for 10 min) and a lower dose (2 mg/kg).
Multiple PTT strategies, i.e. PTT effect resultant from the synergy of GO with other components,
can be another way of achieving tumor ablation with NGO- or GO-based materials. GO and NGO
formulations containing multiple PTT strategies were all able to eradicate tumors in 2 to 6 days [64,
73,92]. Besides the PTT synergic combination, the effective cellular uptake of the formulations might
be, as stated, the explanation for their success in tumor ablation. Table S7 of supplementary materials
summarizes the biodistribution information available for two of these formulations [73,92], and can be
correlated to the successful therapeutic outcomes obtained.
Only one formulation (Au@PLA-(PAH/GO)n) containing a multiple PTT strategy (conferred via
GO and AuNPs) was not able to ablate tumors, although 9 days after treatment the tumor volume
of treated animals was reduced by 80% in comparison with the tumor value of untreated animals
(control) [61]. Despite lacking tumor uptake data, this formulation presented very big sizes (1.5
µm), which may explain a small tumor tissue penetration, also explaining the incomplete tumor
eradication. It is also worthwhile saying that the efficiency obtained is only possible because: (i) PTT is
a type of therapy where the system does not require entering the cell (although being more effective
when the cellular uptake occurs); and (ii) the formulation was intratumorally injected instead of
intravenously injected, thereby permitting that the big sized micromaterial assessed tumor. Moreover,
this study presents a rather short time of evaluation compared with other studies (which always
present more than 10 days of evaluation), and an extension of the period of evaluation would be
required. Finally, intravenous injection is more applicable to therapy where most tumors are not
assessible to intratumoral injection, and in the context of intravenous injection, the bigger sizes of the
system administrated suggests some serious toxicity concerns (e.g., by hemolysis) that may shorten
animals’ survival. Similarly, another formulation IO/GOCOOH was also intratumorally administrated,
and this was for sure a strong reason for the efficient therapeutic outcome obtained (tumor ablation in
2 days) [60]. Thought, in this latter case, the formulation was based in NGO and the lateral dimensions
would be adequate for an intravenous administration.
Regarding GQDs, it seems that there is still room for improving these formulations’ therapeutic
efficiency since only two formulations demonstrated capacity to eradicate the tumor. One of these
formulations (IR780/GQD-FA) was quite effective (tumor ablation in 6 days) given that it presented
a synergic PTT strategy (conferred by GQDs and IR780) that provides the nanosystem with a high
photothermal conversion (87.9%), assuring an effective hyperthermia required to kill the cancer
cells [65]. The biodistribution studies also corroborate this efficiency by proving IR780/GQD-FA tumor
accumulation (Table S7 of the supplementary materials). Another formulation (GQDs) presented a
synergic PTT+PDT strategy (PTT conferred by GQDs and PDT conferred by PpIX) and was able
to ablate the tumor after 20 days of treatment with two laser irradiations at day 1 and 7 [44].
It is thus assumed that this formulation reached tumor cells, although authors do not present
biodistribution data.
A combined PTT+PDT strategy was also used in cGdots (both strategies conferred by GQDs)
and biodistribution studies confirmed that 4 h after injection, GQDs were nonspecifically distributed
in the body (liver, lung, and kidneys) and also distributed in the tumor [45]. Despite the observed
tumor accumulation, there was no successful tumor ablation and the tumor has grown 1.5× larger
in 21 days (though this growth was smaller than that observed in untreated animals). Thus, we can
hypothesize that this can be related not with the absence of tumor uptake, but with the laser irradiation
used. As stated before, these authors used a single laser for PDT and PTT purposes and this laser
is out of the NIR range (λ = 670 nm instead of >800 nm), which is not so adequate to achieve a PTT
effective treatment.
Finally, GQDs were also loaded with DOX in a formulation where DOX was used in a single
chemotherapy strategy, and GO was merely a drug nanocarrier [54]. Also, in this case, the tumor is not
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ablated, and at 23 days after treatment, tumor has grown 6× in size (though this growth was smaller
than that observed in untreated animals). No biodistribution studies are presented, thus it is difficult
to understand the reason why this formulation is not efficient.
4.2. Role of Graphene-Based Nanomaterials in Diagnostic
NGO and GQDs possess appealing optical features that put GBNs in a central role of dye-free
labelling diagnostics. Due to a quantum confinement effect that occurs because NGO and GQDs
dimensions are smaller than their exciton Bohr radii, the nanosized material possess non-blinking
photoluminescence (PL) and photostability [100]. Thus, GQDs fluorescence intensity remains strong
under confocal laser illumination and can serve as a reporter guiding the therapeutic nanosystem
delivery into cells. Accordingly, the studies reported in this review that were based in GQDs have
taken advantage of the PL properties and used it as a diagnostic tool [44,45,49,54,55,63,65,80,82,84,94].
Of additional interest is the fluorescence quenching capability demonstrated by GBNs that result from
fluorescence resonance energy transfer (FRET) or non-radiative dipole–dipole interactions between
fluorescence species and GBNs. This is being used as an additional diagnostic feature that permits
detecting the release of GBNs cargo. Indeed, when GBNs are interacting with the fluorescent cargo
(drug or other active) it reduces its fluorescence emission, but the moment the cargo is released, the
fluorescence emission is reset. This elegant strategy was used in two studies of this review [54,80].
GBNs photothermal conversion properties can also be applied as a therapy-guiding strategy
under a non-labeling IR-TI technique. The application of the NIR laser to induce a PTT effect can be
detected using a visible thermal field image (Table S2 of the supplementary materials), which is very
interesting due to its non-invasive nature and because it provides real-time imaging. Given that PTT
was the therapy modality mostly used by the studies herein revised, IR-TI is, as expected, also widely
used in the studies reported [7,8,48,51,56,58–60,62,64–67,69,73,74,77,87,89,92,93] as both strategies are
often used together.
The third diagnostic modality most described in the studies revised is PAI, which is also different
from GBNs capacity as NIR absorbers or from its easy functionalization with other NIR absorbing
materials, such as gold-based nanomaterials (please see Table S3 of the supplementary materials for a
more detailed explanation of PAI mechanism). Among the GBNs, rGO has attracted attention as a PAI
contrast agent because of its higher NIR absorbance properties. rGO based studies included in this
review took advantage of these properties and have used PAI imaging as a diagnostic tool [59,63,74,79].
Notwithstanding the better intrinsic PAI properties of rGO, GO nanomaterials compensate their lower
NIR absorption with the higher functionalization capacity. Hence, in some studies herein reviewed,
GO nanomaterials were conjugated with other materials as a strategy to enhance NIR absorption and
thereby achieved PAI diagnostic modality [56,71–73].
In some of the studies reviewed, the unique large surface area and easy functionalization of
GBNs has also proved to be very favorable to carry MRI probes [5,48,50,60,80], extending the in vivo
half-life of the MRI contrast agent [60]. Moreover, the large molecular weight of GBNs can decrease the
rotational motion of the water proton, enhancing T1 and T2 relaxivity and leading to a better image.
Similarly, once more due to its large surface area and easy functionalization, GBNs were also explored
as a carrier of radionuclides [51].
Finally, GBNs can also take part in Raman imaging or more effectively in diagnostics based in
surface enhanced Raman spectroscopy (SERS). Regardless of any treatment that have been used, GBNs
normally reveal an appropriate Raman scattering intensity, showing typical bands of D, G, and 2-D
characteristics of vibrational modes in the 1000–3000 cm−1 range. When functionalized with gold and
silver nanoparticles, Raman signals of GBNs are effectively augmented by the surface enhanced Raman
scattering. Taking advantage of this strategy, SERS was used to combine microscope cellular imaging
with Raman spectroscopy, thereby mapping the presence of GBNs in the cellular tumor tissue [68].
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4.3. Role of Graphene-Based Nanomaterials in Toxicity
If we can imagine the high surface of GBNs as an advantage for easy interaction with drugs,
bioactives, genetic material, and other nanosystems, we can also perceive that the interaction of GBNs
with biological structures can be as high, which can be a toxicity concern regarding these highly
reactive nanostructures. It has been reported that the GBNs lateral size and thickness, surface charge,
colloidal stability, and concentration can strongly impact its biological toxicity [39]. For example, lateral
dimensions can dictate the cellular internalization of GBNs (<100 nm) or can promote blood brain
barrier permeation (<35 nm), and some reports indicate liver and lung accumulation for larger-sized
GBNs [39]. Therefore, the major criticism of the studies included in this study must be the scarce
information about the overall nanomaterial size and thickness and surface charge (Table 1). The
evaluation of the colloidal stability of the GBNs developed was even more uncommon in the studies
reviewed. Additionally, other studies made unsatisfactory evaluations based on the short time stability
assessment, such as 3 h, 4 h, 5 h, or 1 day stability [8,50,86]. However, the aggregation nature of less
hydrophilic GBNs, such as GO, particularly under physiological conditions (e.g., in serum), can have
several consequences and are toxic to different cells [39]. Hence, comprehensive physicochemical
characterization is mandatory in future studies of GBNs toxicity.
Colloidal stability of GBNs can be improved by coating their surface with biocompatible materials
that enhance aqueous solubility while assuring a better body distribution. PEG coating is one of
the most used strategies to reach these aims, and was used as a coating and linker of target ligands
in several studies included in this review [5–7,46–51,53,55,56,58,66,67,71,73,75,76,79,81,85–88,91] (see
Table 1). Other strategies used in the revised studies include coating GBNs with OA [57,60,64], HA [62,
69], pDA [59,90], HSA [93], BSA [74], and APGA [77]. OA is a fatty acid that has amphiphilic properties
and can be useful to increase the solubility of GO-based nanosystems. HA is biocompatible, increases
biodistribution, and can additionally serve to target cancer cells (Table 4). Surface modification with
pDA can improve the stability and dispersity of rGOs. An HSA or BSA coating assures increased
plasma circulation and wide body distribution. Finally, APGA is a bacteriomimetic coating that assures
greater body distribution.
The in vitro toxicity evaluation made in the studies herein listed also requires some critical
observations. Some studies have chosen a cell line representative of healthy tissues to evaluate
cytotoxicity while choosing a cancer cell line to evaluate therapeutic outcomes [5,47–49,53,57,58,61,62,
67,68,70,81,82,85]. Yet, most studies used the same cancer cell line to access toxicity and therapeutic
value. However, cancer cell lines can be more resistant or more susceptible according to their genotype.
Therefore, primary cell lines would be more advisable to evaluate cytotoxicity [39]. Furthermore, MTT
was among the most used methods for cell viability evaluation [5–7,44,45,47–50,53,54,56–60,62,64,66,
68,70,73,74,80,82–86,88,90,92,94]. However, MTT has been reported as inadequate for evaluating GBNs
cytotoxicity due to a false positive signal. As a replacement to this widely used method, it would be
recommended, for instance, to use the trypan blue test, which was only used in three studies [61,82,83].
In vivo toxicity evaluation was generally based on the histological observation of healthy tissues
or observation of variations in animal weight after treatment has been applied and no toxicity concerns
were presented in any of the studies where these evaluations were performed (Table 3). Although many
studies have demonstrated bioaccumulation of GBNs in liver and kidneys, few studies have taken
toxicity evaluation further by analyzing important liver and kidney function biochemical parameters.
Liver function biochemical parameters include the serum quantification of hepatic enzymes such
as: alanine aminotransferase (ALT), aspartate transaminase (AST), and alkaline phosphatase (ALP).
Kidney function biochemical parameters include the serum quantification of blood urea nitrogen
(BUN) and creatinine (CR). Only four studies within the 55 included in this review have made a
serum biochemical examination of mice 1 day [77], 7 days [93], 15 days [65], or 50 days [51] after
treatment with GBNs. No significant differences were observed in any of these cases in comparison
with untreated animals and all the parameters were within the reference values.
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Moreover, it is important to carry out the hematological evaluation of: white blood cells, red blood
cells, neutrophilic granulocytes, hemoglobin, mean corpuscular hemoglobin concentration, hematocrit,
and mean platelet volume and distribution. Once more, only three studies of the 55 included in this
review have made this hematological evaluation in mice 15 days [65], 18 days [59], or 50 days [51] after
treatment with GBNs. In all these cases, the parameters were within the reference values.
One good indicator of toxicity is the evaluation of inflammatory response after intravenous
administration by the quantification of cytokines and tumor necrosis factor α (TNF-α). This evaluation
was only made by one study of all the 55 studies included in this review, and the results have
demonstrated an inflammatory response as both TNF-α and proinflammatory cytokines were increased
after intravenous administrations of GBNs [72].
Finally, all the toxicity assessments performed were based on short-term periods, and a longer
period evaluation is necessary.
4.4. Pharmaceutical Applications of Graphene-Based Nanomaterials and Clinical Translation Prospects
The potentiality of exploiting GBNs remarkable physical and optical properties for pharmaceutical
applications has been pursued over the last few years with interesting scientific endeavors that have
proved to be strong contributions in the fields of drug delivery, biosensing, and tissue engineering [101–
103]. In the field of cancer theranostics, it is particularly important that all the successful research
attempts use GBNs to load anticancer drugs, bioactives, or nucleic acids in synergic applications
of chemotherapy, gene therapy, and photothermal/photodynamic therapy [101–103]. Moreover, in
comparison with highly toxic inorganic quantum dots used for theranostic purposes, the ongoing
studies indicate a general satisfactory biocompatibility of GBNs and even when harmful effects
were detected there is a sturdy proof that GBNs toxicity can be modulated and is reliant on specific
applications of this nanomaterial [104]. Notwithstanding these satisfactory signs that GBNs can
be improved to safer forms, there is still a lack of standardization to assure this control [103,104].
Consequently, the European Scientific Committee on Emerging and Newly Identified Health Risks has
included graphene in the classification of dangerous substances, stating that there are still many risk
related knowledge gaps to be filled before considering this nanomaterial safe [105]. This is sadly what
happens with most nanomaterials. Indeed, the toxicity grade for a material can be roughly controlled
by three factors (composition, concentration, and exposure route), whereas for a nanomaterial the
toxicity grade relies on over 10 factors, and it is much more difficult to control these factors or to report
them in a standardized way, such that they can be compared and improved [106].
Therefore, despite the attention-grabbing results obtained to this point and the evident success,
there are still several issues to unravel before a clinical translation is possible. The main issues include:
(i) the dearth of standardization within the production of the different GBNs types; (ii) the lack of
thorough characterization to control lateral size, aggregation state (single vs. few layers of graphene),
colloidal stability, and oxidation grade; (iii) the presence of remnant contaminants resultant from
production processes that may add toxicity to GBNs; (iv) the need to understand how dimensions and
surface chemistry affect cellular uptake or physical adsorption to biomolecules like membranes and
proteins; (v) the necessity to evaluate the generation of ROS and its consequences in healthy tissues; (vi)
the scarce number of biodistribution studies; and (vii) the need to evaluate toxicity in a wider context
that involves not only cytotoxicity studies but also genotoxicity, biodegradation, distribution, and
accumulation into organs, metabolism, and evaluation upon long term exposure. If these main issues
are not addressed, the GBNs developed will have trouble fulfilling the rigid criteria for translation of
novel nanomaterials into significant clinical uses.
Efforts are being made by different scientists to establish important guidelines, tutorials, or
to define challenges that must be pursued to develop low-toxicity and safer nanomaterials that
can be accepted by regulatory authorities. Although being out of the scope of this review, these
attempts of standardization deserve special attention by those that work with GBNs for pharmaceutical
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applications and wish to translate their studies into a clinical use as theranostics (for a more extensive
discussion, please refer to good reviews on the subject [103,104,106]).
Although the translation of GBNs to a clinical context of pharmaceutical applications is still very
far from being possible, it is worth mentioning that the enthusiasm of the scientific community with
the GBNs breakthroughs is shared by the National Institutes of Health (NIH) and its National Institute
of Biomedical Imaging and Bioengineering (NIBIB) program. Indeed, this program is focused on
coordinating engineering and physical sciences with life sciences to propel fundamental research and
medical care and has supported studies included in this review [66,71,88] through the Intramural
Research Program, which indicates an interest in the innovative diagnosis and therapy strategies
provided by GBNs.
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